Drug, bio-affecting and body treating compositions inventions 05/06

20060110322 - Assay for vitamin b12 absorption and method of making labeled vitamin b12: The invention provides methods for labeling vitamin B12 with 14C, 13C, tritium, and deuterium. When radioisotopes are used, the invention provides for methods of labeling B12 with high specific activity. The invention also provides labeled vitamin B12 compositions made in accordance with the invention....

20060110323 - Method of imaging cell death in vivo: The present invention relates to a method and a kit for detecting cell death or another condition characterized by an increase in the extracellular level of phosphatidylserine in a mammalian subject. The method involves administering a radionuclide-labeled compound that comprises a C2 domain of a protein or an active variant...

20060110324 - Human anti-epidermal growth factor receptor single-chain antibodies: Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal...

20060110325 - Serotonin and catecholamine segment optimization technology: Methods of using amino acid precursors of the serotonin and catecholamine neurotransmitter systems and laboratory urinary assay of serotonin and catecholamine neurotransmitter levels for optimal treatment of neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems. The methods may also include determining a...

20060110326 - Toluidine blue o drug substance and use thereof for in vitro staining and chemotherapeutic treatment of dysplastic tissues: The invention comprises an improved process for preparing TBO drug products includes the steps: (1) synthesising an indamine; (2) converting said indamine into an S-indaminyl thiosulfate; and (3) adding an oxidizing catalyst agent, complexing agent, and an acid to said S-indaminyl thiosulfate to formulate TBO and C-4-methyl regioisomer, and derivatives...

20060110327 - Methods and compositions for deterring abuse of orally administered pharmaceutical products: This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended...

20060110331 - Compositions comprising azelastine and methods of use thereof: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize...

20060110330 - Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid: e

20060110329 - Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid:

20060110328 - Method of delivering nasal spray: A method of delivering a nasal spray. A sprayer having a formulation comprising olopatadine is provided. A spray of the formulation is delivered to a subject's nose. The spray may have a spray characteristic comprising a spray pattern having a longest axis of 20-45 mm, a shortest axis of 14-20...

20060110332 - Agent for medicamentous treatment of acute and chronic pain: The invention relates to an agent for the medicamentous treatment of acute and chronic pain, in particular of allodynia and hyperalgesia. Fields of application of the invention are medice and the pharmaceutical industry. A new pharmaceutical composition for the treatment of acute and/or chronic pain, in particular allodynia and hyperalgesiais...

20060110333 - Composition for nasal absorption: This invention attempts to provide a composition for intranasal administration which has markedly lower risk of developing side effects compared to oral formulation, which promptly exhibits analgesic effects, and which has excellent bioavailability. The composition for nasal absorption comprises a carrier of calcium carbonate and/or calcium phosphate having an average...

20060110335 - Aerosol hair styling composition: The present invention is related to a sprayable aerosol foam styling composition. The present invention aims at developing a foaming spray styling product with excellent volume up effect and with quick breaking foam, which makes partial application especially at hair root area possible. Furthermore the objective of the present invention...

20060110334 - Two-compartment aerosol device comprising electrophilic monomers, and use thereof for the cosmetic treatment of the hair: A two-compartment aerosol device comprising: (i) a first compartment comprising a cosmetic composition comprising, in at least one cosmetically acceptable medium, at least one electrophilic monomer, and (ii) a second compartment comprising at least one compressed gas, wherein the first and second compartments provide, during the use of the aerosol...

20060110336 - High-cleaning silica materials and dentifrice containing such: Unique abrasive and/or thickening materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial characteristics depending on the structure of the composite in situ generated material. With low structured composites (as measured via linseed oil absorption levels from 40 to...

20060110338 - High-cleaning/low abrasive silica and materials and dentifrice containing such materials: Unique abrasive and/or thickening materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial characteristics depending on the structure of the composite in situ generated material. With low structured composites (as measured via linseed oil absorption levels from 40 to...

20060110337 - High-cleaning/moderate abrasive silica materials and dentifrice containing such materials: Unique abrasive and/or thickening materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial characteristics depending on the structure of the composite in situ generated material. With low structured composites (as measured via linseed oil absorption levels from 40 to...

20060110339 - Viscosity-modifying silica materials that exhibit low cleaning and abrasive levels and dentifrices thereof: Unique abrasive and/or thickening materials that are in situ generated compositions of precipitated silicas and silica gels are provided. Such compositions exhibit different beneficial characteristics depending on the structure of the composite in situ generated material. With low structured composites (as measured via linseed oil absorption levels from 40 to...

20060110340 - Compositions and methods for whitening, mineralizing and/or fluoridating calcified tissues: Kits and methods that combine whitening/stain removal of teeth with remineralization are disclosed. These kits advantageously comprise separate compositions comprising a soluble calcium salt, a soluble orthophosphate salt, and a soluble peroxide, in order to optimize the stability of these components for storage and/or the activity of these components upon...

20060110341 - Cosmetic compositions containing sophora alopecuroides l. extracts: Disclosed are extracts of Sophora alopecuroides L. as cosmetic skin lightening agents alone or in combination with other skin benefit agents and together with a cosmetic vehicle. Also disclosed are active ingredients in the extracts, including Alopecurone A, Alopecurone B, Sophoraflavone-G, Sophoraflavone-I, Sophoraflavone-K, and mixtures thereof. The inventive extracts, compositions...

20060110342 - Organo-gel formulations for therapeutic applications: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are...

20060110343 - Cosmetic or dermopharmaceutical compositions comprising tyramine derivatives, method for preparing same, and use thereof: The invention concerns cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and their salts. The invention also concerns the method for preparing same and use thereof for reducing pigmaentation....

20060110344 - Water-swellable clay mineral laminated powder, dye/water-swellable clay mineral complex and composition comprising the same: The water-swellable clay mineral laminated powder of the present invention is characterized in that a layer of ionic molecule having two or more ionic functional group is laminated on the surface of a base powder particle, and a layer of water-swellable clay mineral is laminated thereon, and the layers are...

20060110345 - Cosmetic composition containing a polyorganosiloxane polymer: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, containing: at least one structuring agent selected from the group consisting of a polyorganosiloxane-containing polymer, a non-silicone-polyamide copolymer, a wax, and mixtures thereof; (b) a hydrocarbyl-functional silicone polymer; (c) optionally, at least one silicone film former; (d) optionally,...

20060110346 - Transfer-resistant cosmetic compositions: Transfer-resistant cosmetic compositions containing at least one silicone resin and at least one silicone pressure sensitive adhesive and methods of use thereof....

20060110347 - Cosmetic compositions and methods of use: The present invention relates to a cosmetic composition containing a phenyl substituted organosiloxane to provide shine and/or gloss when applied to a keratinous material, such as skin....

20060110348 - Therapeutic composition containing an organosilane quaternary compound and hydrogen peroxide for treating skin disorders and methods of using: Therapeutic skin cleansing and multifunctional coating compositions containing hydrogen peroxide and an organosilane quaternary compound in aqueous formulations are used to treat skin disorders including wounds, abrasions, ulcers, burns, infections, irritations, microbes, soil, water, psoriasis, acne vulgaris, blemishes, age spots, sclerosis, other physical or chemical injuries, and other skin deficiencies....

20060110350 - Composition comprising electrophilic monomers and particular organic salts, and use thereof for cosmetic treatment of keratin materials: The present invention relates to a composition comprising in a cosmetically acceptable medium at least one electrophilic monomer and at least one non-polymeric organic salt having a melting point of less than 60° C., and to its use for the cosmetic treatment of keratin materials. It also relates to a...

20060110349 - Hair care composition: A hair treatment composition comprising (i) 2-hydroxyalkanoic acid and; (ii) 0.1 to 10 wt % of a styling aid....

20060110351 - Use of silanes on cosmetic agents and methods for treating hair: The cosmetic agent contains from 0.01 to 10 percent by weight of at least one silane of formula RmSiX4-m, wherein m=0 to 4, R is a nonhydrolyzable organic group and X is a hydrolysable group, or a salt thereof. The method for improving the condition of hair, particularly in terms...

20060110352 - Cosmetic, pharmaceutical and dermatological compositions: X+ is Li+, Na+, K+, Mg2+/2, Ca2+/2, Al3+/3, NH4+, monoalkylammonium, dialkylammonium, trialkylammonium or tetraalkylammonium, the alkyl substituents of the ammonium ions being independently of one another (C1-C22) alkyl radicals or (C2-C10) hydroxyalkyl radicals, or singly to triply ethoxylated ammonium compounds having the same or different degree of ethoxylation, it being...

20060110353 - Aerosol device comprising at least one high molecular weight polyurethane: Disclosed herein is a composition for cosmetic treatment of keratin materials, packaged in an aerosol device comprising (a) at least one propellant and (b) a hairstyling composition comprising at least one polyurethane having a number-average molecular weight ranging from 400 000 to 5 000 000 g/mol, in a cosmetically acceptable...

20060110354 - Concentrated surface-active preparations: Concentrated surface-active preparations with low viscosity are disclosed, comprising (a) 25 to 55 wt. % amphoteric or zwitter-ionic surfactants (b) 0.01 to 5 wt. % alkaline sulfates, with the proviso that the amounts are made up to 100 wt % with water and, optionally, further electrolytic salts....

20060110355 - Anhydrous cosmetic composition capable of forming an organogel: The present invention relates to an anhydrous cosmetic composition containing, in a physiologically acceptable medium, at least one fatty phase comprising at least one short hydrocarbon-based ester and at least one non-hydrogenated glycerophospholipid, the said short hydrocarbon-based ester and the said non-hydrogenated glycerophospholipid being present therein, respectively, in contents corresponding...

20060110356 - Ophthalmic drug delivery system using polymer micelle: The current situation is such that it is difficult for drugs to reach posterior tissues of an eyeball, such as choroid and retina, with the result that treating diseases in such regions is difficult. Thus, how to attain effective delivery of drugs is of importance. It has been found that...

20060110357 - Bone putty composition that maintains granule suspension at reduced temperatures: The invention is directed to a bone putty composition comprising a carrier formulation comprising water and a carrier substance, and granules wherein said bone putty composition exhibits gel-like Theological properties throughout the temperature range between about body temperature and temperatures approaching about 0° C. The bone putty composition further exhibits...

20060110358 - Combination therapy for treatment of fibrotic disorders: The present invention provides methods of treating a fibrotic disorder. The methods generally involve administering an effective amount of IFN-γ and an effective amount of pirfenidone or a pirfenidone analog....

20060110359 - Cellular delivery of natriuretic peptides: The present invention pertains to a method for treating deficits, such as neurological deficits, caused by focal or generalized edema associated with injury to the central nervous system, heart, liver, and kidney. The present invention further concerns a method for producing natriuretic peptides and pharmaceutical compositions comprising bone marrow stromal...

20060110360 - Methods of treating tumors using natural killer cell lines: This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection...

20060110361 - Methods of making viral particles having a modified cell binding activity and uses thereof: The present invention relates to a method for packaging viral particles such that one or more peptides on the surface of the article are derived from the packaging cell. By incorporating certain peptides it is possible to target viral particles to specific cell types. Such a system is of use,...

20060110363 - Mutant having uracil phosphoribosyl transferase activity: The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them....

20060110362 - Sequences upstream of the carp gene, vectors containing them and uses thereof: The invention relates to novel promoter sequences derived from a portion upstream of the coding sequence of the gene for the CARP protein (Cardiac Ankyrin Repeat Protein), and which are capable of controlling the level and the specificity of expression of a transgene in vivo in cardiac muscle cells. The...

20060110364 - Vector-mediated delivery of polynucleotides encoding soluble vegf receptors: The present invention provides vector compositions for expression of a soluble form of VEGFR3 and methods for their use in the inhibition of one or more of lymphangiogenesis, lymphatic metastasis and angiogenesis, as a therapeutic strategy for treatment of cancer....

20060110377 - Immunologically privileged cells and uses thereof: The invention is directed to immunologically privileged cells, e.g., autologous, allogeneic, and xenogeneic intermediate lobe pituitary cells, for delivering polypeptides, e.g., insulin, to a subject, and to methods of using the same....

20060110376 - Mda-7 and free radicals in the treatment of cancer: The present invention relates to methods of treating a cancer in a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. The present invention further relates to methods of inhibiting proliferation or...

20060110375 - Method for producing cell lines and organs by means of differentiable cells: A method for producing cell lines or individual organs, differentiable donor cells being supplied to a morula or blastocyst which is cultivated under conditions that ensure a further development of the morula or blastocyst in stages in which newly formed cell lines having a higher degree of differentiation occur, as...

20060110367 - Compositions and methods for inhibiting pathogenic growth: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an...

20060110366 - Entomopathogenic microorganism spores carrier and method for controlling harmful insects: The patent describes a method of selective application of entomopathogenic fungi, characterized by employing an attractant-contaminant device in which the spores of said fungus are fixed on an adsorbent material; this same adsorbent material or another, depending on the case, incorporates a specific attractant and is located on an adherent...

20060110365 - Novel bacterium for treatment of disease: This invention relates to compositions comprising a bacterium of the genus Dietzia that is useful for treating paratuberulosis in ruminants and to a method for culturing the bacterium. The invention further relates to methods of treating Johne's disease by administering to a mammal a composition of the invention....

20060110369 - Cell-filled device of modifield cross-section hollow fiber membrane type: To provide a cell-filled device that is suitable for use in, for example, an implantable or circulation type hybrid artificial organ. In a cell-filled device including hollow fiber membranes whose hollow portions are filled with cells, the hollow fiber membranes have modified cross sections, and a cell aggregate provided in...

20060110371 - Control of indoleamine 2,3 deoxygenase expression and activity: The present invention relates to controlling and/or manipulating of dendritic cells by controlling the expression and activity of indoleamine 2,3 deoxygenase expression and activity....

20060110368 - Medium for culturing autologous human progenitor stem cells and applications thereof: Described is a medium for the autologous culture of autologous human progenitor stem cells, which comprises: between 0.1 and 90 wt.-% autologous human serum; between 0.1 and 10,000 UI/ml heparin; between 0.1 and 10,000 UI/ml protamine; and a culture medium consisting of basic nutrients with or without glutamine, in a...

20060110374 - Method to accelerate stem cell recruitment and homing: A method is provided for facilitating treatment of a patient, including stressing a portion of the patient to an extent sufficient to induce homing of progenitor cells to the portion of the patient. A method is additionally provided for use with tissue of a patient, including evaluating an indication of...

20060110373 - Ptu compounds for promoting the in vitro culture of (highly pigmented) melanocytes: A method for promoting the in vitro multiplication of human melanocytes and/or the freezing thereof, notably human melanocytes obtained from individuals of phototype IV, V or VI or from hyperpigmentary lesions, entails introducing into a culture of same, a thus effective amount of at least one 1-phenyl-3-(2-thiazolyl)-2-thiourea (PTU) compound or...

20060110372 - Regulatory cells that control t cell immunoreactivity: [Solution means] CD8+CD122+ T cell subsets are provided as regulatory T cells that suppress activity of activated CD8+ killer T cells. Administration of these T cell subsets can suppress tissue/cell damages. In addition, it has become possible to explore agents that augment immunosuppressive activity of these T cell subsets by...

20060110370 - Treatments for reduction of cytotoxicity and viral contamination of implantable medical devices: A method for treating biomaterial is provided in which a biological tissue, typically after being cross-linked, is contacted with an anticalcification treatment solution under condition effective to render the biomaterial resistant to in vivo calcification upon implantation in a host animal. The anticalcification treatment solutions comprise higher alcohol solutions, a...

20060110378 - Agent for prevention and treatment of inflammatory bowel disease: The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity....

20060110379 - Linkage of agents using microparticles: Methods, products and kits are provided for attaching agents to a skin surface via microparticles using endogenous or exogenous transglutaminase....

20060110380 - Compositions for inhibiting thrombin-induced coagulation and methods of use: A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a...

20060110381 - Hemostatic compositions containing sterile thrombin: The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the...

20060110382 - Antibody peg positional isomers, compositions comprising same, and use thereof: The present invention relates to recombinant protein PEG positional isomers. More specifically, it relates to PEG positional isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNFα). More specifically, it relates to PEG positional isomers of CDP870. The present invention also relates to compositions...

20060110383 - Immunopotentiative composition: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods...

20060110386 - Mammalian cytokines; receptors; related reagents and methods: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described....

20060110385 - Means and methods for diagnosing and treating affective disorders: The present invention relates to nucleic acid molecules, preferably genomic sequences, encoding an ATP-gated ion channel P2X7R which contain a mutation in the 5′UTR or 3′UTR regions, a mutation in exon 3, 5, 6, 8 or 13 or in introns 1, 3, 4, 5, 6, 7, 9, 11 or 12...

20060110384 - Novel proteins and use thereof: The present invention provides a novel secretory/membrane protein associated with adipocyte differentiation and/or metabolism function, specifically, an adipocyte-derived secretory/membrane protein containing amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16,...

20060110387 - Method for treating vasculitis: A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of...

20060110388 - ß binding molecules: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid...

20060110389 - Method of treatment using anti-il-18 antibody: Disclosed are artificially produced peptide capable of neutralizing the biological activities of IL-18, which comprises a part or the whole of the variable regions in anti interleukin 18 antibody, including single chain variable region fragments and humanized antibodies, a process of producing the peptide, and uses thereof. The peptide is...

20060110391 - Compositions and methods for the treatment of body weight disorders, including obesity: The invention provides isolated nucleic acids molecules, designated MKP nucleic acid molecules, which encode novel MAP kinase phosphatase family members, and their use in metabolic disorders. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MKP nucleic acid molecules, host cells into which the expression vectors have...

20060110390 - Inhibition of ku as a treatment for cardiovascular diseases: The present invention provides for methods of treating and preventing cardiovascular diseases, in particular pathological cardiac hypertrophy and chronic heart failure, by applying an inhibitor of Ku. The present invention also provides for methods of screening to find inhibitors of Ku and inhibitors of cardiac hypertrophy and heart failure....

20060110392 - Murine monoclonal antibody (5c8) recognizes t-b cell activating molecule (t-bam) (cd40 ligand) on the surface of t-lymphocytes, compositions containing same and methods of use: The present invention provides a monoclonal antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. This invention also provides compositions comprising the antibody, and hybridomas that produce the antibody. This invention also provides an...

20060110397 - Aimp2-dx2 and its uses: The present invention relates to a variant of AIMP2 lacking exon 2, named as AIMP2-DX2, which is specifically expressed in cancer cells. The AIMP2-DX2 protein and gene can be successfully used in the development of diagnosis and treatment of cancer....

20060110398 - Dap-10 and uses thereof: The present invention relates to methods for identifying and using modulators of DAP10 biological activity in vitro and in vivo that are useful in the treatment of cancer and autoimmunity....

20060110394 - Humanized anti-vla 4 immunoglobulins and uses thereof: The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated...

20060110393 - Novel proteins and use thereof: Compounds that inhibit the expression of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10 or the expression of a gene for the...

20060110395 - Use of crkd as a breast cancer marker and cancer therapy target: In certain aspects, the present invention discloses the use of CRKD as a marker for a cell-proliferative disorder, preferably as a marker for breast cancer. The invention discloses antibodies and fragments thereof which specifically bind CRKD, methods of diagnosing, methods for assessing CRKD status, methods of monitoring the efficacy of...

20060110396 - Use of ligands of the antigen cdw52 for the treatment of diseases that are related to degenerated macrophages: The present invention relates to the use of a ligand of CDw52 for the preparation of a medicament for the treatment of diseases that are related to CDw52 expressing degenerated macrophages. In particular, the present invention relates to the treatment of diseases such as MAS, LCH, HLH, and AML....

20060110399 - Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin: The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation,...

20060110400 - Immunogenic conjugates: The invention relates to an immunogenic conjugate comprising at least one vascular endothelial growth factor (VEGF) peptide moiety coupled to a carrier....

20060110401 - Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof: The invention relates to a peptide mixture including at least two different peptides from the hepatitis C virus (HCV), whereby at least one of them is a peptide from the C protein binding to at least four different HLA-II molecules, the occurrence of which exceeds 5% in the Caucasian population...

20060110402 - Decolorized yeast cell wall fraction: The yeast cell wall fraction comprising cell residues obtained by removing internal soluble components from enzyme-treated yeast, or cell residues obtained by treating the cell residues with acid solution and removing the acid solution-soluble components. By decolorizing the residues with a decolorizing agent, the decolorized yeast cell wall fractions to...

20060110403 - Non-human herpesviruses as vectors: The present invention relates to animal viruses such as animal herpesviruses as a vector for diagnostic, therapeutic and prophylactic delivery of foreign genes and nucleic acids to animals, human or primary cells derived thereof, respectively. By using said viruses, the prevention and treatment of infectious, autoimmune and tumor diseases as...

20060110405 - Plasma or serum fraction for treatment and prevention of viral infections and related conditions: The present invention describes compositions and methods for the treatment and/or prevention of viral infections and related conditions, including HIV infections....

20060110404 - Set of ubiquitous cellular proteins involved in viral life cycle: A method of modulating viral RNA replication and translation, in a eukaryotic cell, of positive-strand viral RNA, comprising the step of contacting a viral RNA-binding protein (vRbp) with a compound that modulates an activity of said protein....

20060110406 - Refrigerator-temperature stable influenza vaccine compositions: Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided....

20060110407 - Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection: The invention provides an immune globulin having a high titre of antibody to Orthopoxvirus, pharmaceutical compositions comprising the immune globulin and methods for making same. In one embodiment the immune globulin is intravenously injectable. The invention also provides a colorimetric assay to detect neutralizing antibodies to vaccinia virus. The invention...

20060110408 - Immunological combination compositions and methods: Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader...

20060110410 - Recombinant toxin fragments: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the...

20060110409 - Targeted agents for nerve regeneration: A conjugate, for delivery of a therapeutic agent to a neuronal cell, comprises the therapeutic agent, a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the binding domain is HC of botulinum C1 toxin or is...

20060110411 - Streptococcus equi vaccine compositions and method of use: This invention relates to compositions comprising live, attenuated Streptococcus equi (S. equi), or a fractional extract of S. equi, in combination with at least one immunostimulant for stimulating mucosal immunity, such as saponin. The invention also relates to methods of preparation and dosage forms containing the composition of the invention...

20060110412 - Vaccine composition: The present invention relates to vaccine compositions for the effective prevention of neisserial, preferably meningococcal, disease. The vaccine of the invention comprise a multivalent meningococcal bled composition comprising at least one bleb with homologous bactericidal activity which is derived from a meningococcal strain with a serosubtype that is prevalent in...

20060110417 - Beauty products and methods: A beauty kit including a beauty product having a beauty product identifier, and at least one template having a facial feature including one or more facial feature identifiers arranged in a predetermined pattern. The facial feature identifiers correspond to the beauty product identifier....

20060110416 - Hydroalcoholic cosmetic compositions: A hydroalcoholic cosmetic composition is provided which when topically applied to the face can shrink skin pores. The composition is focused upon denatured ethyl alcohol utilizing menthol as denaturing agent. Further included in the composition are humectants, preservatives and water. Also described is a method for reducing skin pore size....

20060110413 - Novel molecules dervied from noraporphine: The invention concerns novel molecules derived from noraporphine, as well as cosmetic and dermopharmaceutical compositions containing one or several of said derivatives, alone or combined with a plant extract, in particular glaucium flavum, and particularly preparations for reducing pigmentation, with anti-ageing effect or for slimming....

20060110414 - Oily skin preparation for external use: The objective of this invention is to provide an oily external composition for skin having an excellent rough skin recovering/preventing effect, and wherein powder is well dispersed in oil. An oily external composition for skin of this invention is characterized in that comprising a complex powder (the surface of lipophilic...

20060110415 - Topical delivery system for cosmetic and pharmaceutical agents: This invention relates to topical compositions containing esters of hydroxy acids and their application in the deep-penetration delivery of beneficial cosmetic and pharmaceutical agents....

20060110418 - Water-in-oil emulsions and methods: The present invention provides a process for delivery of water nanoclusters of diameter less than about one nanometer to the skin to yield high epidermal permeability and improved delivery of water to within the outer layer of human skin. This invention provides effective water-cluster-based formulations for a broad range of...

20060110421 - Garbage bag or container: An article, such as a container or bag for garbage, which repels animals such as cats, dogs, rats, and crows. The article may be made from a synthetic resin composition including a synthetic resin and from 10 to 15,000 ppm by weight of a salicylic acid ester, menthol and/or camphor....

20060110420 - Synthetic pheromone compositions: The present invention provides compounds useful for preparing synthetic pheromone compositions that can be used as attractants or inhibitors of insect species. The compositions are useful in the control of navel orangeworm or meal moth insect pests....

20060110419 - Water resistant sunscreen and insect repellant towel: A single-use disposable applicator for applying sunscreen and insect repellent to the skin is a non-woven, woven or porous fibrous material wipe that is saturated with a composition containing a waterproof sunscreen agent and an insect repellent. A film forming agent and solvent may also be present. When rubbed over...

20060110424 - Ceramic and metal compositions: A novel metal/ceramic hybrid material in which the void space of the ceramic is filled with metal. The metal may be bonded to the ceramic, for example by formation of a metal oxide. The metal may be introduced into the ceramic as small particles in a suspension then heated to...

20060110422 - Conversion of calcite powders into macro- and microporous calcium phosphate scaffolds for medical applications: Disclosed is a method for forming carbonated calcium hydroxyapatite. The disclosed method can be used for forming bone cements or optionally cast, cured scaffolds such as may be used in many medical applications, including as implants for bone damage caused by, for instance, trauma, disease, or surgical excision due to...

20060110423 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar....

20060110426 - Cohesive coprecipitates of sulfated polysaccharide and fibrillar protein and use thereof: The present invention concerns cohesive biopolymer gels comprising coprecipitates of sulfated polysaccharides and fibrillar proteins, exemplified by coprecipitates of dextran sulfate and gelatin, useful for clinical applications including as implants for tissue engineering as well as in biotechnology. The cohesive biopolymer gels according to the present invention may be used...

20060110425 - Leech extracts for stents: The invention relates to a stable destabilase complex in the form of a monomer, which is capable of aggregating into a polymer destabilase complex forming a liposome and which can be obtained from medicinal leeches using the following method comprising: affinity chromatography with 6-keto-prostaglandin antibodies which are immobilised on a...

20060110429 - Implant for intraocular drug delivery: An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second,...

20060110428 - Methods and devices for the treatment of ocular conditions: Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device...

20060110427 - Ophthalmic compositions comprising polyether substituted polymers: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300....

20060110430 - Copolymerizable azo compounds and articles containing them: Polymerizable light absorbing azo dyes are disclosed useful as monomers in the formation of devices such as, but not limited to ocular lenses. Specifically, intraocular lenses (IOL) are disclosed wherein one or more of the light absorbing dye is covalently bonded to other structural polymers though ethylene unsaturated groups. The...

20060110432 - Lotion-treated tissue and towel: A paper towel includes: (a) a cellulosic towel web; and (b) a lotion emulsion disposed on the towel web. The lotion emulsion is substantially liquid at room temperature and includes a polar emollient and a non-polar emollient as well as a surfactant composition comprising a nonionic surfactant; wherein the emollients...

20060110431 - Sheets having alternating areas of relatively high and low lotion add-on in the machine direction: Lotion-containing sheets, such as tissue sheets or non-woven sheets, having alternating areas of high and low lotion add-on in the machine direction of the sheet have been found to reduce or eliminate downstream build-up of lotion on process equipment....

20060110433 - Adhesive patch: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with an adhesive base agent and pergolide and/or a pharmaceutically acceptable salt thereof, wherein the adhesive base agent comprises an acrylic polymer including no substantial carboxyl group and hydroxyl group and having self-adhesion...

20060110434 - Drug-containing patch: The problem of the invention is to provide a drug-containing patch which is very favorable in percutaneous absorbability and is excellent in sustainability of the drug efficacy, that is, the drug-containing patch having a sufficient percutaneous absorbability and effect sustainability in a degree to be actually used for therapy of...

20060110435 - Allergy vaccine composition, production method thereof and use of same in allergy treatment: The present invention relates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic...

20060110439 - Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds: The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component....

20060110438 - Liposome stabilizing agent: [wherein M represents a hydrogen atom or a monovalent cation and m, which defines the methylene chain length, represents an integer of 1 to 5], and the other two each represent an chain hydrocarbon group, A1, A2 and A3 are each independently selected from the group consisting of C(O)O, CONH...

20060110441 - Lyophilized liposome formulations and method: Formulations and methods for preparing a lyophilized composition comprising liposomes comprised of an unsaturated lipid and a hydrophobic drug associated with the liposome, and a cryoprotectant in a solution at a selected concentration. The phase transition temperature of the lipid is greater than the freezing point of the solution at...

20060110440 - Method and system for biasing cellular development: Compositions and methods comprising siRNA targeted to APP mRNA are advantageously used to transfect stem cells and bias the cells against differentiating into glial type neural cells. The siRNA of the invention causes RNAi-mediated silencing of the APP mRNA. The inventors have discovered that expression APP induces gliogenesis, i.e., promotes...

20060110436 - Phospholipid derivative: A phospholipid derivative, utilizable for modification of liposomes and the like, which is a copolymer containing, as essential component units, a component unit A represented by the formula (1), a component unit B represented by the formula (2A) and/or the formula (2B), and a component unit C represented by the...

20060110437 - Synthesis and self-assembly of abc triblock bola peptide: The present invention provides for bola amphiphiles compositions which have more than one lyophilic (hydrophilic) head group and a hydrophobic (hydrophobic) moiety capable of hydrogen bonding with other bola amphiphiles. These bola amphiphiles are capable of self assembling into micelles. The advantage of these bola amphiphiles is that they may...

20060110442 - Coated sherical seamless filled capsules: Described is a spherical coated capsule comprising (a) a coating-free capsule having (i) a liquid or viscous core and (ii) a seamless solid shell surrounding this core, and (b) a seamless, solid coating surrounding said coating-free capsule, wherein—the diameter of the coated capsule is in the range of 5-9 mm,...

20060110443 - Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form: A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The...

20060110450 - Bilayer tablet of telmisartan and amlodipine: A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the calcium channel blocker amlodipine from a disintegrating or eroding tablet matrix....

20060110453 - Calcium hypochlorite blended tablets: A non-Division 5.1 Oxidizer tablet consisting essentially of a blend of hydrated calcium hypochlorite with magnesium sulfate heptahydrate, wherein the blend contains at least about 17% by weight of water based on the total weight of the blend; contains from about 0.1% to about 10% of lime based on the...

20060110448 - Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a local anaesthetic such as lidocaine, polidocanol or prilocaine are provided, which are useful in particular in the treatment of dermatological diseases such as atopic, contact or seborrhoeic dermatitis, psoriasis, acne, rosacea, post-peel, pruritus, skin burning, or...

20060110447 - Controlled and continued delivery of rifaximin and/or other substances: A gum-like device is designed for the controlled and continued delivery of rifaximin, without producing the usually intense red coloration, for the resolution of the infections and the reduction of the inflammation in the oral cavity and in the laryngo-pharyngeal one. The device also protects either the gum or the...

20060110446 - Deferacirox dispersible tablets: The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet....

20060110445 - Dispersible tablet for oral administration: The present invention relates to a process for the preparation of a dispersible tablet dosage form comprising β-lactam antibiotics for oral administration....

20060110452 - Dosage forms of risedronate: Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine...

20060110451 - Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives: The present invention provides solid dosage formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives and processes for their manufacture. In some particular embodiments, the present invention provides novel formulations of the antipsychotic and antiobesity agent (9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline hydrochloride (Compound A.HCl)....

20060110449 - Pharmaceutical composition: The present invention relates to formulations useful for treating respiratory disorders associated with the production of mucus glycoprotein, skin disorders, and allergic conjunctivitis while substantially reducing adverse effects associated with the administration of non-selective anti-cholinergic agents and methods of use thereof....

20060110444 - Solid dosage form comprising a fibrate: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations....

20060110455 - Antiviral product, use and formulation thereof: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more...

20060110454 - Extended release formulation of pramipexole dihydrochloride: An extended release composition of Pramipexole or a pharmaceutical acceptable salt thereof, wherein the active agent is coated on a non pareil inert core, the drug loaded core is further coated with a polymeric layer which enables the release of the active agent over an extended period and optionally the...

20060110456 - Method for biocidal and/or biostatic treatment and compositions therefor: There is provided a method of biocidal and/or biostatic treatment and compounds and compositions thereof. In particular, there is provided a composition comprising at least one compound having the formula R1R2NR3, wherein R1, R2 and R3, are selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, cycloalkyl, cycloaryl, cycloheteroaryl,...

20060110457 - Heat cured gel and method of making: A method of curing and corresponding resulting non-polymeric cross-linked gel are provided. The cross-linked gel can be combined with a medical device structure. The cross-linked gel can provide anti-adhesion characteristics, in addition to improved healing and anti-inflammatory response. The cross-linked gel is generally formed of a naturally occurring oil, or...

20060110458 - Sustained release drug carrier: The present invention aims to provide completely biodegradable and biocompatible sustained-release carriers for proteins or peptides, which allow encapsulation of the proteins or peptides at high encapsulation rates without inhibiting their biological activity. The present invention provides a method for preparing a sustained-release carrier, wherein in a solution in the...

20060110459 - Triple natural polymer viscoelastic composition: A triple natural polymer viscoelastic composition is disclosed. By combining glucosamine sulfate (“GS”), sodium hyaluronate (“HA”) and chondroitin sulfate (“CS”), the triple natural polymer viscoelastic compositions of this invention can provide a viscoelastic agent at a surgical site that not only serves as a protective agent to ocular tissues, but...

20060110462 - Nanoparticulate compositions of tubulin inhibitor compounds: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment...

20060110461 - Non-food and non-pharmaceutical use of a selected anhydrous dextrose composition: The present invention relates to the non-food and non-pharmaceutical use of a powder anhydrous dextrose composition, characterized by the fact that the composition has: a) a particle size such that: at most 4% of its particles (expressed as a volume) have a size at most equal to 40 microns, and...

20060110460 - Prolonged release biodegradable microspheres and method for preparing same: The invention concerns a method for preparing a pharmaceutical composition in the form of microspheres with prolonged release of a water-soluble active principle. The invention is characterized in that it comprises the following successive steps: dissolving an active principle in an appropriate amount of water; emulsifying the resulting aqueous solution...

20060110464 - Material encapsulation system: A material encapsulation and release system having a first zone (1) containing a first amount of material (2) bound by a first capsule wall (3) and, if desired, a second zone (4) containing a second amount of material (5) bound by a second capsule wall (6), each capsule wall responsive...

20060110463 - Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of amoxicillin, said formulations consisting of suspensions of coated particles of amoxicillin (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the amoxicillin...

20060110465 - Compositions addressing inflammation and/or degenerative disorders: Compositions for primarily addressing degenerative complaints, in particular joint related conditions such as arthritis and rheumatism, in which there may also be associated inflammation, are provided. Other potential uses are also discussed, as well as prophylactic and curative applications. Preferred embodiments incorporate green-lip mussel products (particularly GLME) with shark cartilage...

20060110466 - Natural water wipes: The natural water wipe is unlike others in this category because it is devoid of any added substance, active ingredient or solution. Water will be the only natural ingredient used to avoid irritation or allergic reactions to the skin or to any body parts such as the mouth, eyes, ears...

20060110467 - Cancer chemotherapy: e

20060110469 - Angelicae sinensis extracts useful for treatment of cancers: The invention provides an acetone extract, chloroform extract or hexane extract of Angelicae sinensis and/or the active components purified therefrom, such as n-butylidenephthalide, which are effective in treating cancers....

20060110468 - Herbal formulations for arthritis: The present invention provides an oral formulation comprising ingredients extracted from Caulis Sinomenii, Radix Aconiti Lateralis Preparata, Radix Paeoniae Alba, Cortex Moutan, and Rhizoma Curcumae Longae. The formulation has anti-arthritic, anti-inflammatory and anti-nociceptive properties and is suitable for the treatment of arthritis, symptoms associated with arthritis and other similar conditions....

20060110470 - Pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof: The present invention relates to compound Chinese medicine preparation, and is especially one drug addiction stopping Chinese medicine prepared with red sage, mankshood, cassia, amomum fruit and other Chinese medicinal materials. The present invention also discloses its preparation process and application....

20060110471 - Essential oil blend for inhalation: The present invention provides a novel blend of essential oils and herbs. A blend of the invention may be used to treat nausea. A blend of the invention may be used to provide a calming, soothing feeling. Optionally the novel blend of the invention is introduced into the body of...

20060110472 - Use of allicin as insect repellent and insecticide in agricultural crops: The invention provides methods for: (a) protecting agricultural crops, particularly fruits and vegetables, against insects, by treating the crops with allicin prior to harvesting; (b) protecting fruits and vegetables from decay and extending the shelf life thereof by treating the fruits and vegetables with allicin after harvesting; and (c) repelling...

20060110477 - Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction: Improved nutraceutical compositions and methods for supporting and promoting healthy sexual function, for preventing sexual dysfunction, or for treatment of sexual dysfunction. The compositions include a portion of the plant Sophora flavescens or an extract of the plant Sophora flavescens, such as sophoflavescenol. The compositions also include Vitex agnus-castus extract,...

20060110475 - Composition containing in combination at least one bourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent: The present invention relates to a composition comprising, in combination: at least one marrow oil and at least one borage oil. The invention also relates to such a composition, for its use as a medicinal product, as a dermatological or dermocosmetic agent, or as a nutraceutical agent, especially for its...

20060110473 - Composition containing radix codonopsis pilosulae and radix astragali and hedysari, method of producing it and use thereof: The invention discloses a composition containing radix Codonopsis pilosulae and radix Astragali and hedysari, The main component is made from radix Codonopsis pilosulae and radix Astragali and hedyyari in certain rate. The invention also discloses the method of producing it and the use for producing immune system-regulated agent and these...

20060110478 - Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction: Improved delivery systems and delivery methods for supporting and promoting healthy sexual function, for preventing sexual dysfunction, or for treatment of sexual dysfunction. A compositions including one or more cGMP-specific PDE5 inhibitors and/or dopaminergic agonists is administered in the form of a breath-care strip, mint or lozenge, or a food...

20060110476 - Dietary foodstuff for positively influencing cardiovascular health: This invention relates to a dietary foodstuff containing at least one carob product, particularly water-insoluble carob fibers, and at least one n-3 fatty acid. The invention also relates to a method for producing active substance combinations of this type and to the use thereof....

20060110474 - Rubrofusarin glycoside-containing composition: There is provided an oral composition capable of strimulating intracellular biosynthesis of glutathione in order to maintain in-vivo (i.e., in tissues and cells) glutathione level at a high level, by adding an active ingredient other than an amino acid precursor from a viewpoint of increasing intracellular glutathione synthesis, as a...

20060110479 - Natural composition for curing hepatitis-b, methods for making the same and pharmaceutical formulations thereof: Disclosed herein is a natural antiviral composition comprising extracts of plant Cyperus rotundus and/or plant Cyperus scariosus and a pharmaceutically acceptable carrier. Also disclosed are methods of making the plant extract, methods for preparing the composition and methods of treating diseases related to acute and chronic hepatitis B and other...

20060110480 - Pharmaceutical composition comprising extracts of radix clematidis for treating and preventing diabetes, diabetic complications, insulin resistance and insulin resistance syndrome: Disclosed is a composition comprising extracts of Radix Clematidis for preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome. The composition of the present invention for preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome, comprises extracts of Radix Clematidis in an amount of...

20060110481 - Compositions containing vitex agnus-castus berry oil for cosmeceutical applications and method of isolation of the active component: The invention relates to the effective use of compositions containing a specially prepared oil from Vitex agnus castus berry as a potent anti-acne agent which is to be applied topically. The invention also describes the process of fractionation of the oil, identification of the active component using bioautographic technique, and...

20060110482 - Transmucosal oral delivery device: Provided, among other things, is a method of treating an indication of mucosal or adjacent tissue comprising periodically applying to mucosa at or adjacent to disease affected tissue a delivery device comprising a backing layer and an adhesive reservoir comprising an effective amount of appropriate composition of plant extract(s) comprising...

20060104897 - Method for diagnosing and treating nis-expressing carcinomas and metastases: The present invention relates to a method for diagnosing and/or treating sodium-iodide symporter (NIS)-expressing primary carcinomas and metastases, preferably glandular carcinomas, in particular carcinomas of the thyroid, of the salivary gland, of the uterus and carcinomas of the breast, and to a pharmacological composition comprising substances which induce and/or increase...

20060104898 - Ligands to radiation-induced molecules: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor...

20060104899 - Production and use of novel peptide-based agents for use with bi-specific antibodies: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic...

20060104900 - Polymer precursors of radiolabeled compounds, and methods of making and using the same: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds....

20060104902 - Method of preselection patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy: The present invention generally relates to methods of preselecting patients for treatment with an anti-VEGF therapy, anti-HIF-1 therapy or anti-thioredoxin therapy. Aspects of the invention combine methods of dynamic contrast enhanced-MRI and diffusion weighted-MRI for the detection of tumor histology. The methodology disclosed herein detects tissue blood volume, tumor vascularity,...

20060104901 - Preventing or treating epithelial tissue damage or hair loss: The present invention pertains to a method for preventing and/or treating epithelial tissue damage, such as is effected by inflammatory reactions, ageing or cancer and/or to prevent and/or treat hair loss. In particular, the present invention relates to substances and/or compositions modifying, in particular blocking endogenous CD1d function. According to...

20060104904 - Method of evaluating plant protection: A method is provided for evaluating a protected plant having a protection mechanism. A population of immature insects (i.e., larvae or nymphs) belonging to an insect species having a plurality of instars is first exposed to the protected plant such that the protected plant is at least contacted thereby. The...

20060104905 - Methods of screening agents for activity using teleosts: The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity in teleosts are provided....

20060104903 - Model for evaluating the efficacy of locally applied antiproliferatives or other agents on neointimal hyperplasia, immunohistochemical and vascular cell cycle changes in balloon-injured rat carotid arteries: A methodology for evaluating the efficacy of locally applied antiproliferatives and/or other therapeutic agents on neointimal hyperplasia, as well as immunohistochemical and vascular cell cycle changes, in balloon-injured rat carotid arteries may be utilized for determining the efficacy of treatments in humans....

20060104906 - Method and apparatus for producing contrast agents for magnetic resonance imaging: The present invention relates to an arrangement and a method for providing contrast agent for e.g. MRI (Magnetic Resonance Imaging) and NMR (Nuclear Magnetic Resonance) applications. The method according to the invention comprises the steps of obtaining (100) a solution in a solvent of a hydrogenatable, unsaturated substrate compound and...

20060104908 - Polymerization method for the synthesis of polypeptide imaging agents: A method for synthesizing extended poly(amino acids) conjugated to imaging agents, such as DTPA, is disclosed. The amino acid is initially conjugated to the imaging agent at the monomer stage, followed by formation of the corresponding N-carboxyanhydride. The method utilizes catalyzed ring opening polymerization of the N-carboxyanhydride of the amino...

20060104907 - Biologically potent analogues of the dmt-tic pharmacophore and methods of use: m

20060104909 - Abuse-resistant pharmaceutical compositions: An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprises a matrix, in which said particles are distributed, and which renders...

20060104910 - Over dosage indicating medicated film strip: A stack of at least two layers of an edible film comprising overlying and underlying film layers; each edible film contains a unit dosage of medication; each film within said stack having a unique marking, shape, cut-out, wording, color, texture, or other indicia such that when one or more adjacent...

20060104914 - Device and method for treatment of eyelid diseases: A container has an impermeable outer membrane sized to fit generally within the peri-orbital region and sufficiently flexible to mold to the structure of the closed eye. Heat which is generated by an exothermic reaction inside the container, which provides steady-state heat to the eyelids. A soft, non-abrasive, lint-free material...

20060104911 - Foamable alcohol: The present invention is a foamable alcohol having at least one active ingredient. The active ingredient can be a prescription or non-prescription drug or medication. It either works on the skin or is absorbed transdermally and works on the body. Alcohol, such as ethyl alcohol is combined with a fluoro-surfactant,...

20060104913 - Inhalable formulations for treating pulmonary hypertension and methods of using same: The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any...

20060104912 - Mousse composition: A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive...

20060104915 - Aerosol dentifrice formulation: An aerosol dentifrice formulation is provided comprising a high water based system, a specific particle size abrasive and a liquified gas propellant, characterised in that the liquified gas comprises 2-8 wt % of a non-hydrocarbon and 2-6 wt % of a hydrocarbon propellant. There is provided a dentifrice formulation comprising...

20060104916 - Method and apparatus for enhanced size reduction of particles: The present invention provides methods and apparatus for producing particles via supercritical fluid processing. In one embodiment, the method includes expanding a supercritical fluid plasticized melt across a pressure drop to form solid composite particles that are simultaneously dispersed, foamed and cooled, and milling the solid particles produced to achieve...

20060104917 - Stable pharmaceutical products: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide....

20060104918 - Antiperspirant aerosol compositions: A suspension antiperspirant aerosol composition comprising milled activated aluminium chlorohydrate (AACH) having non-hollow particles and a carrier fluid comprising a masking oil of viscosity 103 mm2/s or greater gives good antiperspirancey and reduced levels of white deposits....

20060104919 - Foamable alcohol: The present invention is a foamable alcohol health, beauty, skin care, nail care and/or haircare product. Alcohol, such as ethyl alcohol is combined with a fluoro-surfactant, at least one active ingredient and water. Other ingredients can be added. The fluoro-surfactant reduces the surface tension of the alcohol allowing it to...

20060104920 - Flavored hemostatic and acid etching compositions: Hemostatic compositions and dental etching compositions for oral use include methyl salicylate in order to mask or disguise their otherwise unpleasant taste. The methyl salicylate, hemostatic and/or dental etching agent are dispersed within an aqueous carrier, which may be liquid or viscous as desired. In order to increase the stickiness...

20060104921 - Novel gum delivery systems and methods of making thereof: A substrate having about 0.5 wt % to about 25 wt % gum incorporated upon it is provided that provides the benefit of delayed viscosity when incorporated into a person care composition such as a toothpaste. Also disclosed is a method for forming gum incorporated onto or into a substrate...

20060104922 - Tooth whitening compositions and methods for using the same: A tooth whitening system that effectively conceals tooth discoloration within a short period of time. The system includes a single, spectrally pure, substantially violet dye and a carrier for applying the dye to teeth....

20060104925 - Particle comprising a host lattice and a guest, its preparation and use in ultraviolet light screening compositions: A UV screening composition comprising novel particles which are capable of absorbing UV light so that electrons and positively charged holes are formed within the particles is disclosed. These particles comprise a host lattice incorporating a second component to provide luminescence trap sites and/or killer sites, said second component being...

20060104924 - Photostable photoprotective compositions comprising dibenzoylmethane and arylalkyl benzoate compounds and a compound that accepts the excited triplet level energy of said dibenzoylmethane(s): Topically applicable, improvedly photostabilized, photoprotective cosmetic/dermatological compositions contain (i) an effective UV-screening amount of at least one dibenzoylmethane sunscreen and an effective photostabilizing amount of (ii) at least one arylalkyl benzoate compound and (iii) at least one compound accepting the excited triplet level energy of said at least one dibenzoylmethane...

20060104923 - Sunscreen compositions containing fluorinated alkyl ethers: Disclosed are sunscreen compositions containing at least one sunscreen agent, a volatile solvent comprising a cosmetically acceptable lower alkanol, and a fluorinated alkyl ether, and methods of making and using same....

20060104927 - Compound, process for producing the same and use thereof: The compound of the present invention is a component originated from a natural material, camu camu (Myrciaria dubia), has strong antioxidative activity and stable whitening effect, and is represented by the formula (1). The antioxidant, whitening agent, skin preparation for external use, cosmetics, and food of the present invention are...

20060104926 - Whitening agent, skin preparation for external use and cosmetic: The invention relates to a whitening agent that makes effective use of camu camu seeds, which have conventionally been discarded, and that has high safety and whitening effect useful in cosmetics and the like, as well as skin preparations for external use and cosmetics containing the whitening agent. The whitening...

20060104929 - Aqueous emulsion comprising an organosilicon polymer, process for producing the same and cosmetic materials: An aqueous emulsion comprises as the disperse phase obtained by emulsifying a mixture consisting of (A) a linear organosilicon polymer whose main chain is composed of diorganosiloxane units and alkylene units and (B) an oil that is liquid at room temperature. The emulsion can be produced by emulsifying a mixture...

20060104930 - Use of hydrophilic-rich alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymers as emulsifiers for the preparation of cosmetic o/w emulsions of improved aesthetic properties and mildness:

20060104938 - Methods of setting up, caring for and later removing a temporary rasta hairstyle: A method of setting up, caring for and later removing a temporary rasta hairstyle is disclosed. This method includes applying a roughness-increasing substance to the hair to roughen the hair, optionally, but preferably, applying an adherence-increasing substance to the hair to increase adherence of hairs to each other, and subsequently...

20060104931 - Cosmetic treatment article comprising substrate and gel composition: Disclosed are cosmetic treatment articles comprising: (1) a water-insoluble substrate; (2) a gel composition comprising: (a) a first gel forming composition comprising a water soluble polymeric gelling agent and (b) a second gel forming composition comprising a gel strengthening agent; and (3) preferably, a treatment composition comprising a rheology modifier....

20060104932 - Exfoliating skin care product: Exfoliating skin care products which rapidly dissolve in water, yet are non-irritating to the skin, are provided. These exfoliating skin care products comprise a water soluble particulate material of a large enough particle size such that the user of the exfoliating skin care product can tactilely feel the particulate material...

20060104933 - Process for preparing scented cellulosics and products prepared thereby: The present invention provides a process for optimizing the fragrance of a scented cellulosic....

20060104935 - Controlled dissolution crosslinked protein crystals: The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in...

20060104934 - Cosmetic composition comprising ubiquitin: The invention relates to a cosmetic composition comprising ubiquitin in combination with a cosmetically-acceptable medium....

20060104936 - Charging/separating cosmetic makeup compositions for keratin fibers: The present invention relates to a cosmetic composition for making up keratin fibers, characterized in that it comprises at least one wax, in that it has a solids content of greater than or equal to 45.5% by weight and a plateau Gp modulus of rigidity of greater than or equal...

20060104928 - Thermal hair straightening and conditioning composition: A thermal hair straightening and conditioning composition and method for rendering hair more manageable, minimizing static charge, tangling, and scattering of the hair is disclosed. A gelatinous aqueous thermal hair straightening and conditioning composition is provided that imparts a firm and silky look and feel to hair and inhibits wind...

20060104937 - Scalp treatment: A composition for topical application to the scalp comprises (i) an anti-dandruff agent; (ii) conjugated linoleic acid; and (iii) a cosmetically acceptable diluent or carrier....

20060104939 - Degrading lignocellulosic materials: A method for the degradation of lignocellulosic material by applying to the material an enzyme composition which is a mixture comprising at least a cellulase, xylanase and ligninase, and optionally other enzymes, such as a protease, lipase, urease, uricase, and/or pectinase, to solubilise or decompose the material at least partially....

20060104940 - Cosmetic, pharmaceutical and dermatological preparations comprising copolymer waxes: Cosmetic, pharmaceutical and dermatological preparations are described which contain copolymer waxes. The copolymer waxes contain structural units which are formally derived from α-olefins having 26 to 60 carbon atoms, derivatives of (meth)acrylic acid such as esters, amides or salts and optionally further monomers....

20060104941 - Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing...

20060104942 - Remedies for ischemic disease: An effective remedy for ischemic disease, which contains human granulocyte colony-stimulating factor (human G-CSF) and hepatocyte growth factor (HGF) as active ingredients, is disclosed. By administering this remedy, an effective therapy particularly for obstructive arteriosclerosis is provided which can eliminate drawbacks with conventional therapies such as kinesitherapy, pharmacotherapy, revascularization and...

20060104944 - Activators and inhibitors of protease activated receptor2 (par2) and methods of use: The present invention relates to a method of treating a subject for a condition mediated by a deficiency in angiogenesis by administering to the subject a PAR2 agonist under conditions effective to promote angiogenesis and treat the conditions mediated by a deficiency in angiogenesis. A further aspect of the present...

20060104945 - Enhancement of b cell proliferation by il-15: Compositions and methods for modulating the growth, proliferation, and/or differentiation of B-cells in the germinal center are disclosed, and include use of IL-15 inhibitors, antagonists, and agonists. The compositions and methods find use in treating B-cell-related disorders, including neoplasms of the B-cell lineage....

20060104943 - Vaccine comprising il-13 and an adjuvant: The present invention relates to IL-13 vaccines and their use in the treatment of diseases that are treatable with neutralization of IL-13 such as COPD, asthema and atopic disorders such as hayfever, contact allergies and atopic dermatitis. The vaccines of the present invention comprise an IL-13 immunogen and an adjuvant...

20060104946 - Method for treating inflammatory bowel disease: A method for treating inflammatory bowel disease by administering interferon beta in conjunction with factor XIII to a mammal afflicted with the disease. The IBD may either be ulcerative colitis or Crohn's disease. The factor XIII used may be recombinant or nonrecombinant. The interferon beta used can be naturally occurring...

20060104947 - Remedy for pemphigoid: An agent for treatment of pemphigoid is provided. For use as an agent for treatment of pemphigoid, IFN-γ is administered in a dose of 2,000,000 JRU once daily for 7 days by intravenous drip infusion. Depending on symptoms, side effects and age of a patient, the dose can be change,...

20060104948 - Interferon immunotherapy: A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient...

20060104951 - Akt and regulation of ra synovial fibroblast apoptosis: The administration of an Akt inhibitor in a suitable carrier to a rheumatoid arthritis synovial fibroblast affords a process for inducing rheumatoid arthritis synovial fibroblast apoptosis. The Akt inhibitor is administered either as an active molecule or as a gene sequence expressible within rheumatoid arthritis synovial fibroblast cells. The gene...

20060104949 - Expression control using variable intergenic sequences: The present invention relates to a method of production of antibodies wherein the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in which the two cistrons are linked by an optimised intergenic sequence....

20060104952 - Genomic barrier to viral disease: The present disclosure describes methods for the formation of a genomic barrier to viral infection as a means preventing or mediating viral disease. The formation of a genomic barrier would complement a person's immune system response based on the ability of a specific person to create a genomic environment which...

20060104956 - Methods and compositions for inhibiting the function of polynucleotide sequences: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous...

20060104953 - Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof: The present invention relates to providing human primary fibroblasts with a nucleic acid of interest with, among others, the purpose to improve the taking of, for example, skin transplants, particularly, methods of transducing fibroblasts with the nucleic acid of interest by means of gene delivery vehicles, in particular chimeric recombinant...

20060104950 - Methods of tranducing genes into t cells: The present invention provides methods of transducing a gene into activated T cells comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides a method of preparing T cells transduced with a foreign gene comprising the step of contacting a paramyxovirus vector with activated...

20060104955 - Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria: The invention can be summarized as follows. According to the present invention there is provided an attenuated, tumour-targeting bacterium comprising a heterologous nucleotide sequence encoding a protein permitting the accumulation of a radionuclide within the bacterium. The heterologous nucleotide sequence may encode a sodium iodide symporter protein. The invention also...

20060104954 - Recombinant adeno-associated virus virions for the treatment of lysosomal disorders: AAV expression vectors and recombinant virions produced using these vectors, which include genes coding for enzymes defective or missing in lysosomal storage disorders, are described. These recombinant AAV virions are useful in the treatment of a variety of lysosomal storage disorders and the methods described herein provide for long-term, sustained...

20060104961 - Mechanisms of myoblast transfer in treating heart failure: Bioengineering the regenerative heart provides a novel treatment for heart failure. On May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine...

20060104964 - Recombinant sequence, its preparation and use: An isolated, purified or recombinant nucleic acid sequence is disclosed, comprising: (a) a sequence that encodes both an angiogenic factor antagonist and a vascular endothelial structure regulator; (b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or (c) a sequence substantially homologous to or...

20060104962 - Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith: Transfected, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin−HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye and a gene operably encoding an antiangiogenic fragment of tryptophanyl tRNA synthetase (TrpRS). Preferably at least about 20% of the cells...

20060104963 - Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells: Transfected, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells express the cell surface antigen CD31. The transfected stem cells express an...

20060104965 - Method for increasing lactose tolerance in mammals exhibiting lactose intolerance: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day...

20060104957 - Bioartificial lacrimal gland: The present invention provides a bioartificial lacrimal gland which contains at least one unit that includes (a) a permeable housing having an interior and an exterior; (b) an outlet connecting the housing interior to the housing exterior; and (c) a population of lacrimal epithelial cells within the housing interior....

20060104959 - Cell lines: The present invention relates to cells obtainable from cell lines having the ECACC Accession Nos 04091601, 04110301 and 04092302....

20060104960 - Pharmaceuticals containing retinal stem cells: The invention relates to stem cells isolated from the retina of mammals and retinal cells differentiated from these stem cells. The invention also relates to a method of isolating retinal stem cells and inducing retinal stem cells to produce retinal cells. Retinal stem cells may also be induced in vivo...

20060104958 - Tissue engineered cardiac constructs: Tissue-engineered bio-active cardiac constructs (BACCS) are described. These constructs are prepared by combining a suspension of isolated cells with a suitable support such as an extra-cellular filament or matrix. The isolated-cell component of the constructs is prepared from mammalian cardiac tissue, or from cells that differentiate into cardiac tissue. Extra-cellular...

20060104966 - Transglutaminase linkage of agents to tissue: Methods, products and kits are provided for attaching agents to body tissues using transglutaminase....

20060104967 - Method of converting the state of proteins: Since the mechanism of conversion of the state of actin and myosin or the filaments containing myosin from the relaxed to the catch had not been totally clear and its reconstitution was not easily carried out, a method of converting the state of the muscle proteins from the relaxed state,...

20060104968 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties...

20060104969 - Compositions and methods for enhancing structural and functional nervous system reorganization and recovery: The present invention provides methods and compositions for enhancing recovery in a subject suffering from damage to the nervous system. In particular, the invention includes a method for promoting recovery and/or reorganization in the nervous system of a subject in need of enhancement of recovery and/or reorganization of the nervous...

20060104970 - Biological glue based on thrombin-conjugated nanoparticles: Thrombin-conjugated nanoparticles, wherein said nanoparticles comprise one or more organic and/or inorganic compounds and process for preparing the same are provided. The thrombin-conjugated nanoparticles are suitable for use in the preparation of fibrin-based biological sealant....

20060104972 - Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11...

20060104971 - Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof: Multivalent antibody constructs that are specific for the human lymphotoxin beta receptor, as well as their use in treating cancer and inhibiting tumor volume in a subject are disclosed....

20060104973 - Reducing ngr-p75 mediated inhibition of axon regeneration: Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration....

20060104975 - C-type lectin binding molecules, identification and uses thereof: C-type lectins are involved in the binding of many different types of carbohydrates. Considering their diversity in kind and expression of different types of cells, the influence of such binding is very diverse and dependent among others on the type of cell, the environment of the cell and the type...

20060104974 - Cd147 binding molecules as therapeutics: In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in...

20060104976 - Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells: The present invention relates to the identification and use of high efficacy vaccine antigens which modulate antigen presenting cells....

20060104977 - Methods of therapy and diagnosis using immunotargeting of cd84hy1-expressing cells: Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of...

20060104978 - Methods and compositions for pdgf-c activation and inhibition: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of...

20060104979 - Mt-sp1 polynucleotides and polypeptides: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and...

20060104980 - Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes: Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be...

20060104984 - Methods and compositions for use in treating cancer: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer....

20060104981 - Prophylactic/therapeutic agent for cancer: A compound or its salt that regulates (preferably inhibits) the activity of a protein comprising the same or substantially the same amino acid sequence as represented by SEQ ID NO: 1, a compound or its salt that regulates (preferably inhibits) the expression of a gene for the protein, an antisense...

20060104982 - Therapies for seizure disorders using rlip76: The present invention is a composition identified as a coding region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1 and directly effects transport activity and membrane association of the ralA binding protein 1. The composition is used to identify chemical...

20060104983 - Therapies for the regulation of insulin and glucose using rlip76: The present invention includes methods and compositions used to regulate glucose and insulin levels in subjects in need thereof. Compositions are regions that recognize a ralA binding protein 1 and directly affects transport activity and membrane association of the ralA binding protein 1. The compositions are used to identify chemical...

20060104985 - Dengue virus infection inhibitor: A dengue virus infection inhibitor, as a drug effectively inhibiting the infection with dengue virus, which is characterized by containing, as the active ingredient, at least a carbohydrate molecule having as an essential constituent an oligosaccharide chain represented by the following formula (I): Hex1NAcβ1-3Hex2β1-4Hex1β1- (I) (wherein Hex1 and Hex2 represent...

20060104987 - Novel nucleic acid molecules correlated with the rhesus weak d phenotype: The present invention relates to novel nucleic acid molecules encoding a Rhesus D antigen contributing to the weak D phenotype which are characterized by one or a combination of missense mutations or by a gene conversion involving exons 6 to 9 of the RHD and RHCE genes. The present invention...

20060104986 - Yeast-dendritic cell vaccines and uses thereof: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a...

20060104988 - Vaccines against hiv-1 tat protein to generate neutralizing antibodies: The present invention relates to compositions and methods for eliciting a neutralizing antibody response specific to HIV Tat proteins. Also disclosed are vaccines including amino terminus Tat linear epitope peptide fragments having the amino terminus sequence of the HIV Tat protein, optionally conjugated to a carrier protein. The invention relates...

20060104989 - Essential novel bacterial polypeptides: The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides....

20060104990 - Outer surface proteins, their genes, and their use: According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a...

20060104991 - Methods for constructing antibiotic resistance free vaccines: The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same....

20060104992 - Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv: The inventions provide an isolated antiviral peptide characterized by the amino acid sequence GDEPLENYLDTEYF (SEQ ID:NO 1) and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. It has postulated anti-retroviral activity in vivo, particularly anti-HIV-1 activity. The inventions further provide pharmaceutical...

20060104993 - Methods and compositions for immunizing against pseudomonas infection: Methods and compositions for inducing an immune response against Pseudomonas aeruginosa are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and a Pseudomonas pilin peptide comprising an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), wherein the chimeric...

20060104994 - Clostridial toxin pharmaceutical composition containing a gelatin fragment: A botulinum toxin pharmaceutical formulation comprising a botulinum toxin and a low molecular weight recombinant or native gelatin fragment suitable for administration to a human patient, and methods for treating patients with various diseases and afflictions using the formulation....

20060104995 - Methods for treating headache: The present invention features a method for treating a headache in an acute pain medication overuse patient. In some embodiments, the method comprises the step of local administration of a botulinum toxin to a patient who is an acute pain medication overuse patient, thereby both countering a headache exacerbation caused...

20060104996 - Methods for producing oocysts: The present invention provides improved methods and compositions for producing oocysts. The oocysts produced according to the invention find use in the manufacture of vaccines. In preferred embodiments, the present invention provides methods and compositions for the production of Eimeria oocysts. Vaccines containing Eimeria oocysts, sporocysts and/or sporozoites produced according...

20060104999 - Composition for solubilization of paclitaxel and preparation method thereof: The present invention relates to a paclitaxel composition and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4˜90% by weight of at least one selected from the monoglycerides, 0.01˜90% by weight of at least one oil and 0.01˜20% by weight of paclitaxel. Also the present invention relates...

20060105000 - Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil: The invention provides a composition of matter for treating infected skin and mucousal membranes, said composition comprising at least one anti-microbial drug; and at least one essential oil, in combination with a substantially, alcohol-free carrier system, said carrier being selected from a liquid carrier or a semi-solid carrier, said carrier...

20060104997 - Monoterpene compositions and uses thereof: The present invention relates to pharmaceutical compositions and methods for the mucosal and oral administration of monoterpenes and derivatives thereof. The compositions of this invention further comprise one or more surfactants and cosolvents and are in the form of self-emulsifying compositions. The compositions of the invention may further comprise water-insoluble...

20060105001 - Smart drug delivery system: The present invention provides prodrug and multi-prodrug complexes comprising drugs specifically bound to synthetic receptors in such a manner that active drug becomes available only in the presence of a targeted pathophysiologic receptor. Methods for preparation and use of these prodrug complexes in drug delivery systems are also provided....

20060104998 - Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof: The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the Formula (I): wherein R1, R3-R5, A, D, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the...

20060105003 - Composition comprising at least one conductive polymer and at least one rigid non-film-forming particle, and processes for the uses thereof: The disclosure relates to a composition comprising, in a cosmetically acceptable medium, (a) at least one rigid non-film-forming particle and (b) at least one conductive polymer. The disclosure also relates to a process for treating keratin fibers, a process for shaping and/or holding the hairstyle, and a process for giving...

20060105004 - Cosmetic compositions comprising calcium silicates: Disclosed is a fluid cosmetic composition comprising a sebum-absorbing calcium silicate. These cosmetic compositions provide effective, long-lasting facial cosmetic coverage that is highly resistant to the sebum-caused deterioration that results in the discoloration and fading typically experienced by conventional cosmetic compositions after a sustained period of use. The cosmetic composition...

20060105002 - Preparation of lactic acid derivatives and their use: The present invention relates to preparing lactic acid derivatives that are useful as odorants and monomers for polymer synthesis....

20060105005 - Skin care formulation containing whole egg powder: A skin care formulation is provided, the formulation comprises dehydrated whole egg, at least one emollient substance and at least one humectant substance and the dehydrated whole egg is hydrated during the manufacturing process....

20060105006 - Use of metalloprotease inhibitors to induce and/or stimulate the growth of head hair or other hairs and/or to slow down their loss: A method for inducing and/or stimulating the growth of hair and/or slowing down hair loss comprising administering an effective amount of at least one metalloprotease inhibitor or any functional biological equivalent thereof and an acceptable carrier therefor....

20060105009 - Compositions: A new association of pesticides with synergic activity against insects, arachnida and worms....

20060105008 - Compositions and methods for reducing vaginal ph: This invention relates to aqueous buffered compositions and methods for lowering vaginal pH and reducing the level of self-perceived vaginal odor. Such compositions may be applied to the vaginal area to lower vaginal pH and assist in maintaining such pH over a period of time....

20060105007 - Stable matrix emulsion concentrates and stable aqueous and/or organic solvent compositions containing biocides: A stable matrix emulsion concentrate of a biocide, e.g. 3-iodopropynyl-2-butyl carbamate (IPBC) and/or a triazole fungicide, and stable aqueous and/or organic solvent formulations thereof, i.e. dilutable in water and/or an organic solvent are provided, which are particularly useful for treating wood products to provide protection against microorganisms and insects....

20060105010 - Bladder implant: The invention prevents the occurrence of bladder infections by means of a silver-doped bladder implant that, upon placement at the entry of the bladder, results in the elimination of up to 95% of the germs arriving in the bladder via the urethra. The device not only prevents the occurrence of...

20060105011 - Method and apparatus for computer-aided tissue engineering for modeling, design and freeform fabrication of tissue scaffolds, constructs, and devices: A process and apparatus are provided for manufacturing complex parts and devices which utilize a CAD environment to design a part or device to be created (FIG. 1); Boolean, scaling, smoothing, mirroring, or other operations to modify the CAD design; a software interface to convert the CAD designed part (Data...

20060105012 - Pro-fibrotic coatings: Pro-fibrotic coatings for medical articles are described that include a pro-fibrotic polymer such as collagen. The pro-fibrotic coatings can also include a thromboresistant polymer. The coatings can be formed by activation of photoreactive groups pendent or independent of the coating materials....

20060105014 - Compositions, systems and methods for treatment of defects in blood vessels: Methods and systems are provided for treating a vascular structure having a defect, for example, a cerebral artery having a weakened wall that has formed an aneurysm. The methods include substantially entrapping a quantity of blood within a vascular defect, and introducing a quantity of a crosslinking agent, for example...

20060105016 - Device compatible with magnetic resonance imaging: A plurality of coated layers is disposed on an implanted device. The materials and electrical parameters of the coated layers are chosen and the geometry of the coated layers is arranged so that incident electromagnetic radiation induces currents in the coated layers that have a predetermined phase and amplitude relationship...

20060105017 - Methods for treatment of wounds using time release compositions: A method for treatment of wounds associated with the insertion of a medical implant, wherein an inorganic therapeutic agent containing potassium, rubidium, calcium and zinc cations is applied to the wound site on a silicone or bioabsorbable membrane. The therapeutic composition is provided in a long lasting, timed delivery formulation...

20060105013 - Osteopontin-coated surfaces and methods of use: An osteopontin containing implant which increases the rate of osseointegration and the percentage of bone apposition is described. In one embodiment, the implant includes osteopontin or an active fragment thereof or an active peptide derived thereform. In another embodiment, the implant includes a material suitable for use in vivo within...

20060105015 - System and method for attaching soft tissue to an implant: One embodiment of the present invention is directed to compositions and methods for enhancing attachment of soft tissues to a metal prosthetic device. In one embodiment a construct is provided comprising a metal implant having a porous metal region, wherein said porous region exhibits a nano-textured surface, and a biocompatible...

20060105019 - Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders: Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque....

20060105018 - Therapeutic driving layer for a medical device: The present invention regards the delivery of therapeutic at a target site. Systems that employ the present invention may employ a medical device sized to be inserted into a target site, a driving layer covering at least a portion of an accessible surface of the medical device, and a therapeutic...

20060105021 - Cholesterol-reducing liquid: A dry-blended cholesterol-reducing composition and its method of manufacture are disclosed herein, wherein such cholesterol-reducing composition is formed by adding a dry-blended mixture including cholesterol-lowering active ingredients to a liquid, wherein the dry-blended mixture evenly disperses in the liquid for human consumption. The cholesterol-lowering active ingredients include phytosterols, inositol, policosanol,...

20060105020 - Highly absorbable taste and odor free organic nutritional supplement made from food by products and mixable with solids and liquids, and method of making such: The process includes a mix of cheese production whey (residual liquid from cheese manufacture) with blood of slaughter animals, whereby a biological process is undertaken with whole whey and through a thermal process proteins are precipitated and the yeast cells of the biomass are inactivated, both of which are separated...

20060105022 - Process for preparing crosslinked hyaluronic acid gel: [PROBLEMS] A novel process which can simply prepare a crosslinked hyaluronic acid gel having a small crosslinking agent content and exhibiting excellent viscoelasticity is provided. [MEANS TO SOLVE] A method of producing cross-linking hyaluronic acid gel, comprising stirring and mixing a mixture containing 20 W/V % or more of hyaluronic...

20060105023 - Treatment of neurological disorders with nicotine: Neurological disorders, such as migraine and addiction to smoking tobacco, are treated by the administration of an effective amount of nicotine, preferably in a water solution of nicotine processed to diminish the odor, taste, and smell of nicotine....

20060105024 - Granulates containing feed-enzymes: The present invention describes a process for the preparation of an enzyme-containing granulate wherein an aqueous enzyme-containing liquid is, optionally supplemented with a solid carrier and/or additive ingredients, processed into granules, dried and subsequently coated with a dispersion containing particles of a hydrophobic substance. The hydrophobic substance may be a...

20060105025 - Recovery pet chews: Extruded and densified recovery, ingestible pet chews, comprising a blend of an emulsion, starch, protein, plasticizing substance and water, which indicate recovery, resistance to fracturing and resistance to crumbling properties over the chew-life of the pet chews....

20060105026 - Tissue-adhesive formulations: A tissue-adhesive formulation consists of a naturally occurring or synthetic polymerisable and/or cross-linkable material in particulate form, the polymerisable and/or cross-linkable material being in admixture with particulate material comprising tissue-reactive functional groups. The formulation may be used in the preparation of a tissue-adhesive sheet, by applying the formulation to at...

20060105029 - Instant patch for dermal drug delivery: The present invention is drawn toward systems, devices, and methods of dermal drug delivery. The system can comprise a gel-triggering agent and a drug-containing composition including a drug and a gelling agent, wherein the drug-containing composition forms a soft, coherent solid when contacted with the gel-triggering agent. A cavity patch...

20060105027 - Method for treating skin ulcers: An improved method of treatment of ulcer-type skin conditions. The method is primarily characterized by applying a combination of nitroglycerin and arginine. The composition may be applied topically or injectablely. Also, the method provides for the skin wound to be substantially free from debridement or washing. Further, the skin wound...

20060105028 - Systems and methods for treating warts: The present invention is drawn to systems and methods for treating warts. The system can comprise a wart treatment formulation comprising a substance for treating warts and a cavity patch comprising an open cavity being configured to become a closed cavity upon application and adherence to a skin surface. The...

20060105030 - Transdermal therapeutic system: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal...

20060105031 - Accelerating recovery from trauma: Mammalian patients suffering from physical trauma, or about to likely suffer such trauma (by surgical treatment, or by suffering unanticipated accidental injuries, battle injuries or the like) are treated to lessen the severity of or accelerate the recovery from such consequently sustained trauma, by administering to the patient immune system-modifying...

20060105032 - Multiple sclerosis treatment: Symptoms, including biochemical correlates, of multiple sclerosis (MS) in a mammal are beneficially affected by administering to the mammal small doses of bodies, such as liposomes, of a size resembling that of mammalian cells, the bodies having phosphate glycerol head groups presented exteriorly on their surfaces. Preferred are liposomes comprised...

20060105033 - Dietary composition containing conjugated linoleic acid and calcium for improved health: The invention provides a composition for oral administration comprising a mixture of conjugated linoleic acid (CLA), docosahexaenoic acid “DHA”, vitamin E, vitamin C, vitamin B6, vitamin B12, folic acid, and calcium together with a suitable carrier. These compositions are particularly useful as dietary supplements administered to reduce the risk factors...

20060105034 - Formulation and delivery method to enhance antioxidant potency of vitamin e: A formulation to deliver a full-spectrum of Vitamin E isomers for improved antioxidant capacity, bioavailability, dissolution and efficacy. The formulation includes dl-α-tocopheryl acetate or dl-α-tocopheryl succinate (synthetic Vitamin E), natural Vitamin E and mixed tocopherols, such as α-, β-, γ- and δ-tocopherol, as well as four isomers (α, β, γ...

20060105035 - Sustained release heterodisperse hydrogel systems for insoluble drugs: A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic...

20060105037 - Sustained release pharmaceutical preparations and methods for producing the same: An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate....

20060105036 - Threo-dops controlled release formulation: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an...

20060105038 - Taste-masked pharmaceutical compositions prepared by coacervation: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles...

20060105039 - Taste-masked pharmaceutical compositions with gastrosoluble pore-formers: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the...

20060105040 - Pharmaceutical tablet and process for making thereof: A pharmaceutical tablet as well as a process for manufacturing the tablet are described herein. More specifically, a tablet and process of manufacture is described where a drug having a defined rate of delivery is applied by compression onto a compressible coating deposited on a tablet having the same or...

20060105041 - 4-hydroxy tamoxifen gel formulations: Pharmaceutical compositions comprising 4-hydroxy tamoxifen in an amount of 0.105-0.950% by weight effectively deliver the 4-hydroxy tamoxifen. Such compositions, including gels, can treat or prevent benign breast disease, scarring or a keloid, gynecomastia, breast cancer, mastalgia, or a condition involving dense breast tissue....

20060105042 - Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof: The present invention provides methods for making, delivering and using formulations that combine a therapeutically active agent(s) (such as for example a Rho antagonist(s)) and a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo (such as for example tissue adhesives), to injured nerves to promote repair...

20060105043 - Porous nanostructures and methods involving the same: A method for simultaneously detecting and separating a target analyte such as a protein or other macromolecule that includes providing a porous silicon matrix on the silicon substrate, exposing the porous silicon matrix to an environment suspect of containing the target analyte, observing optical reflectivity of the porous silicon matrix;...

20060105045 - Cyclodextrin solubilizers for liquid and semi-solid formulations: This invention is directed to compositions comprising a water-miscible organic solvent or solvent mixture and one or more cyclodextrin derivatives soluble in the organic water-miscible organic solvent or solvent mixture. In some embodiments, the composition comprises one or more compounds. The invention is further directed to capsules containing the compositions...

20060105046 - Polymer conjugates of opioid antagonists: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the...

20060105044 - Sustained release formulations of sotalol: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In...

20060105047 - Novel prepolymers useful in biomedical devices: A novel polyurethane based prepolymer useful in biomedical devices which provides high oxygen permeability and superior physical properties....

20060105050 - Compositions comprising fenofibrate and simvastatin: The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor simvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCsimvastatin) of between about 800 and about...

20060105049 - Folic acid-chitosan-dna nanoparticles: The present invention relates to a non-viral novel drug delivery system. Nanoparticles comprising folic acid and chitosan are used to deliver a therapeutic agent of interest to the cell for various therapeutic applications....

20060105051 - Manufacture of particles for pulmonary drug delivery by carbon dioxide assisted nebulization: Methods of making porous particles by using carbon dioxide assisted nebulization (CAN) technology in combination with spray drying technologies are disclosed. As the mixture of carbon dioxide (CO2) and the solvent with drug matrix is expanded through the nebulizer to atmospheric conditions, the resulting aerosol contains fine micro-bubbles and/or micro-droplets...

20060105048 - Remedy: It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized,...

20060105052 - Cationic nanoparticle having an inorganic core: wherein R1independently at each occurrence is an alkoxy group, a hydroxyl group, a halide, an alkyl group, or hydrogen, and wherein at least one R1 of the three R1s is not an alkyl group. A nanocomplex having a cationic nanoparticle and at least one oligonucleotide attached to the cationic nanoparticle...

20060105053 - Microsphere filled polymer composites: Block copolymers are suitable additives for polymeric composites containing microspheres. The block copolymers have at least one segment that is capable of interacting with the microspheres thereby enhancing the physical characteristics of the composition....

20060105054 - Urinary tract tissue graft compositions and methods for producing same: A method for repairing damaged or diseased urinary tract tissue includes providing a urinary tract tissue graft composition that includes a distal ileal segment of small intestinal submucosa. The distal ileal segment of small intestinal submucosa may be utilized as an unseeded tissue graft composition, or the distal ileal segment...

20060105055 - Arthritis and muscle soothing formulation containing whole egg powder: A muscle soothing skin care formulation is provided, the formulation comprises whole egg, at least one emollient substance, at least one humectant substance and at least one muscle soothing substance such as menthol and camphor. The formulation is designed to treat arthritis and muscle aches and pains....

20060105056 - Oxygenated albumin for use as blood and blood extender: The compositions described herein comprise oxygenated albumin in an aqueous sterile physiological or serum solution. The albumin is oxygenated to increase the oxygen content up to O2 saturation with clinically useful oxygen gas. The preferred oxygen-saturated preparations, containing albumin in concentrations from about 5% w/v to about 25% w/v, are...

20060105057 - Compositions using tetrasilver tetroxide and methods for management of skin conditions using same: Pharmaceutical compositions including tetrasilver tetroxide (Ag4O4), such as in crystalline form, and methods of using such compositions for the prevention, treatment, and management various of dermatological skin conditions and diseases. In one embodiment, these compositions are substantially free of added persulfates. These dermatological conditions and diseases that may be prevented,...

20060105058 - Facial pack and bathing compositions based on hwangto (korean loess) and preparation thereof: Disclosed are a facial pack composition and a bathing composition based on loess, and methods for preparing the same. The bathing composition makes a user feel refreshed, prevents arteriosclerosis and fat accumulation in human bodies, is useful for the treatment of maturating diseases such as dermatophytosis and dermatitis and stimulates...

20060105059 - Fruit and/or vegetable derived composition: There is provided a process for making a composition suitable for topical application comprising the steps of a) heating at least one fruit and/or vegetable pulp to up to a temperature in the range of about 40° C. to 100° C.; b) mixing between 1 and 40% w/w of a...

20060105060 - Medicinal drug and methods of manufacturing the same: The present invention includes a medicinal drug comprising an Axonopus extract and Ludwigia extract dissolved in a pharmacologically acceptable solvent. The present invention also includes a method of treating inflammation. The method includes administering to a subject an extract of Ludwigia, which is preferably dissolved in a pharmacologically acceptable solvent....

20060105061 - Galenical composition: A method for preventing metal-induced oxidative damage of hepatocytes, for inhibiting hepatocellular carcinogenesis, or for increasing carcinogen-metabolizing enzyme activity, which comprises administering to a subject an effective amount of an extract of a galenical composition comprising Panax pseudoginseng, Eucommiae ulmoides and Polygonati Rhizoma as essential components....

20060105062 - Composition and method for modulating addictive behaviors: Improved compositions and methods useful in the treatment and prevention of impulsive, compulsive, reward seeking, and other addictive behaviors, including applications involving the behavioral/cognitive process of assigning importance, maintaining attention, and assessing salience. The composition includes Vitex agnus-castus (Chastetree berry) extract in an effective amount for supporting and promoting a...

20060105063 - Synergic combination of compositions containing aloe vera isolates and their therapeutic application: Synergic compositions containing an Aloe vera isolate and optionally, a prebiotic, Fucose, and/or other treatment regimens, as well as methods for their preparation and use in treating disease conditions such as neurological syndromes, chronic pain illnesses, inflammatory bowel diseases, and viral diseases are disclosed....

20060105064 - Composition for treating skin ulcers: An improved composition for treatment of ulcer-type skin conditions. The composition is primarily characterized by a combination of nitroglycerin and arginine. Other embodiments comprise emollient cream, mineral oil, tumeric powder, folic acid, vitamin B12, and zinc citrate. The composition is particulary effective in improving blood flow in the underlying capillary...

20060105066 - Compounds for altering food intake in humans: The present invention relates to a process of providing an extract containing at least one simmondsin compound. The extract is provided from jojoba plant, and used as a dietary supplement for use in a weight control regiment in humans. The present invention also provides a method of treating an overweight...

20060105065 - Liquid seasoning: A liquid seasoning, comprising: (A) 9% by weight or less of salt; (B) 0.5 to 4.2% by weight of potassium; and (C) 0.05 to 20% by weight of a substance having an antihypertensive effect. Salty taste is sufficiently provided despite its low salt concentration, and pharmacological functions such as an...

20060105067 - Medicament containing epidemium extract for treatment of prostatic hyperplasia and prostatitis: This present invention relates to a method for extracting Epimedium herb to prepare flavones and polysaccharides combinations in which their ratios vary from 2:8 to 8:2 by weight and applying these extracted compositions in treatment of prostatic hyperplasia. Total flavones of the extracts are in the range of 20-90% and...

20060105068 - Dietary supplement formulations containing hoodia gordonii: A diet composition for weight control including effective amounts of hoodia gordonii cactus (whole plant/less roots), alone or together with any or all of chromium, vanadium amino acid chelate, glucomannan, sodium carboxymethylcellulose, citrus naringinine, green tea, cocoa extract, glucosamine HCl, ma huang, 3-acetyl-7-oxo-dehydroepiandrosterone, and coleus forskohlii. The effective amounts may...

20060105069 - Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant: The present invention relates to pharmaceutical, therapeutic, nutritional, cosmetic, and dermatological compositions derived from the preicarp (rind) of the Garcinia mangostana L plant and the novel extraction processes used to produce those compositions. Specifically, the present invention relates, in part, to an approximately 0.01% to about 80% mixture of a...

20060105070 - Dioscorea extracts: An extract from a tuber of a Dioscorea plant. Also disclosed is a composition containing an extract from a tuber of a Dioscorea plant and a cytokine, as well as methods of enhancing proliferation of bone marrow or spleen cells and stimulating regeneration of a specific lineage of hematopoietic cells....

20060105071 - Blood-viscosity reducing agent: A blood-viscosity reducing agent contains a protein derived from Bacillus subtilis natto and including, sequentially from an amino group terminal, a first structural amino acid sequence having alanine, threonine, aspartic acid, glycine, valine, glutamic acid, tryptophan, asparagine, valine, aspartic acid, glutamine, isoleucine, aspartic acid, alanine, proline, lysine, alanine, tryptophan, alanine,...

20060099141 - Radiation sensitive liposomes: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to...

20060099143 - Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis: A method of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. An antibody that has the amino acid sequences i) to iii), the amino acid sequences iv) to vi), or the...

20060099142 - Cancer associated araf1 protein kinase and its uses: Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further...

20060099144 - Tumor association of mdl-1 and methods: The invention provides methods for detecting, diagnosing, localizing and imaging tumors. The invention also relates to methods for detecting, diagnosing, localizing, imaging and treating cancer....

20060099145 - Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system: e

20060099148 - Methods and compositions for imaging: The present invention is directed to compositions useful as imaging agents for use in monitoring atherosclerotic plaque regression using, for example, MRI, CT, Gamma-scintigraphy, or optical imaging techniques. Methods and compositions of using the same are described....

20060099147 - Functionalized encapsulated fluorescent nanocrystals: Provided are a functionalized, encapsulated fluorescent nanocrystal comprising a liposome having encapsulated therein one or more fluorescent nanocrystals; use of the functionalized, encapsulated fluorescent nanocrystals in detection systems; and a method of producing functionalized, encapsulated fluorescent nanocrystals. A method of using the functionalized encapsulated fluorescent nanocrystals having affinity molecule bound...

20060099146 - Nir-sensitive nanoparticle: wherein X=1-9; Y=0-9; n=0-9; Z=1-9; W=0-9; m=0-9; each of R1, R2, R3 and R4, if present, is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 aryl, HS, COOH, NH2 or OH; R5 is COOH, NH2 or OH; with the proviso that n+m is <10; (b) an amino acid...

20060099149 - Metered dose inhaler product: The present invention relates to the provision and use of pressurised metered dose inhalers (MDIs) for the effective administration of pharmaceutical aerosol formulations. Such formulations comprise a drug, a propellant comprising one of either 1,1,1,2-tetrafluoroethane (HFA 134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFA227) or a mixture thereof, a cosolvent having a higher polarity...

20060099150 - Compositions and methods for the transport of biologically active agents across cellular barriers: Disclosed herein are complexes and compounds that pass through cellular barriers to deliver compounds into, through and out of cells, and methods of producing and using such complexes and compounds. The complexes and compounds of the invention comprise a biologically active portion and a targeting element directed to a ligand...

20060099151 - Stable foam cream: The invention relates to a stable foam cream, containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to heat treatment. The invention also relates to the production thereof....

20060099152 - Zinc-containing dentifrice compositions having improved taste: The present invention relates to antimicrobial oral compositions comprising a water-soluble zinc salt wherein a surfactant selected from alkali metal or ammonium salts of alkyl sulfoacetate, dialkyl sulfosuccinate, dialkyl sulfosuccinamate; and mixtures thereof; is used in an amount effective to reduce the astringency of the zinc salt....

20060099153 - Oral preparation and chewing gum: The invention provides an oral preparation or a chewing gum comprising an organic acid and/or inorganic acid and a fluoride ion supplying compound, wherein a light scattering layer is formed inside enamel of the teeth when the oral preparation or the chewing gum is applied to teeth. An internal tooth...

20060099156 - Dental whitening compositions: A two-component whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be an unfoamed, a foamed or a foamable composition. The system has a first component with at least one peroxide compound, at least one source of phosphate and at least one gelling agent; and...

20060099155 - Dental whitening systems: A system and method for tooth whitening are disclosed wherein at least one peroxide-containing gel and at least one transition metal compound-containing gel, particularly at least one lower atomic number transition metal compound, more particularly at least a ferrous compound including gluconate, sulfate, nitrate, acetate or mixtures thereof, are applied...

20060099154 - Teeth whitening method, products, system and method of conducting business thereby: The present invention provides an improved dental whitening method and composition, and method of conducting business thereby, having reduced teeth and oral tissue sensitivity, which comprises the application of a whitening composition, which is either preceded or followed by the application of a teeth desensitizing composition, and optionally the prior,...

20060099157 - Ether alcohols used as solvents and emulsifiers and dispersions containing said ether alcohols: R2 is hydrogen or C1-4-alkyl, n is on average 1 to 100, m is on average 0 to n/2 EO, PO are basic building blocks derived from ethylene oxide and propylene oxide, which may be present in any order if both building blocks are present, are used as solvents, solubility...

20060099159 - Novel amine, amide, sulphonamide and carbamate derivatives of benzalmalonic salts and photoprotective cosmetic compositions comprised thereof: Stable, topically applicable cosmetic/dermatological sunscreen compositions, well suited for the UV-photoprotection of human skin/keratinous materials, contain a thus effective amount of at least one novel amine, amide, sulphonamide or carbamate substituted benzalmalonic salt compound....

20060099158 - Preparation containing conjugated linoleic alcohol: Compositions comprising at least one conjugated linoleyl alcohol component selected from the group consisting of cis- and trans-isomers of 6,8-octadecadienol, 7,9-octadecadienol, 8,10-octadecadienol, 9, 11-octadecadienol, 10,12-octadecadienol and 11,13-octadecadienol are described along with their use in oral and topical applications for humans and animals....

20060099160 - Composition intended to be applied to the skin and the integuments: The present invention relates to a composition intended to be applied to the skin, the lips and/or the integuments, comprising, in a physiologically acceptable medium, at least one composite pigment comprising:—a mineral core,—at least one organic pigment at least partially covering the mineral core,and—at least one binder for fixing the...

20060099162 - Oral care implement: An oral care implement is provided having a handle and a head with tooth cleaning elements extending from fixed pods. Additional tooth cleaning elements extend from one or more central pods suspended between the fixed pods via a bridge. The bridge may be formed from an elastomer and permit the...

20060099161 - Skin preparations for external use: A skin treatment composition comprising anti-bacterial zeolite and trisalt ethylenediaminehydroxyethyl triacetate. A skin treatment composition comprising anti-bacterial zeolite and alum and/or dried alum. A skin treatment composition comprising anti-bacterial zeolite and polyoxyethylene polyoxypropylene 2-decyltetradecyl ether. The object is to provide a skin treatment composition containing anti-bacterial zeolite that exhibits the...

20060099163 - Anhydrous antiperspirant composition: An anhydrous composition of dry aluminum chloride hexahydrate in Castor Oil CP or in Dehydrated Castor Oil particularly suitable for the treatment of localized hyperhidrosis....

20060099164 - Composition for coating keratin fibres, comprising a high dry extract that contains a sequenched polymer: Composition for coating keratin fibres with a high dry extract comprising a block polymer A subject of the invention is a composition for coating keratin fibres comprising, in a cosmetically acceptable medium, a block polymer, a styrene-free block polymer, the said composition having a dry matter or dry extract content...

20060099165 - Fatty acid esters of ethoxylated alkylglucosides: A mixture of fatty acid esters of ethoxylated alkylglcosides of formula I is useful as a refatting agent in cosmetic formulations....

20060099166 - Honey-based skin care preparation: The invention relates to a honey-based skin care preparation, wherein the honey is entrapped within an aqueous polymeric gel. The skin care preparation is suitable for healing wounds on the one hand and for cosmetic use on the other hand. Preferably, the skin care preparation comprises a humectant, such as...

20060099167 - Personal care composition containing a non-guar galactomannan polymer derivative: Personal care compositions comprise (a) from about from about 5 wt. % to about 35 wt. % of a detersive surfactant; (b) at least about 0.05 wt. % of a galactomannan polymer derivative having a mannose to galactose ratio of greater than 2:1 on a monomer to monomer basis, the...

20060099168 - Polymeric compositions for sustained release of volatile materials: Polymeric compositions which are able to incorporate and sustainedly release volatile materials (e.g. perfumes) based on the combined use of low melting point polyamide polymers with a polar thermoplastic elastomer. Such compositions are easy to process at low temperature and are able to stably incorporate and gradually release large amounts...

20060099169 - Toxin binding compositions: Methods and compositions for the treatment of toxin-mediated diseases are provided herein. One aspect of the invention is oligosaccharide-based therapeutics that interact with toxins and methods of uses thereof. In one embodiment the oligosaccharide-based therapeutics of the invention comprise polymeric particles with attached oligosaccharide binding moieties. The compositions of the...

20060099170 - Compositions for inducing increased levels of beta-chemokines and methods of use therefor: The present invention relates to compositions and methods for inducing increased levels and availability of β-chemokines by administering to a subject at least one G1 phase arresting compound, wherein the increased levels and availability of β-chemokines block chemokine/viral receptors thereby preventing or treating viral infections....

20060099172 - Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of prophylaxis and treatment of avian influenza: A method of treating avian influenza comprising transdermally administering imiquimod cream and DHEA cream while simultaneously administering valacyclovir tablets....

20060099171 - Mouse glucocorticoid-induced tnf receptor ligand is costimulatory for t cells: The present invention provides mGITRL proteins, nucleotide molecules encoding same, mGITRL messenger RNA molecules, methods of expressing a recombinant gene in an immune cell and of stimulating CD4+CD25− T cells, comprising same or comprising agonist anti-GITR antibodies...

20060099174 - Interferon-alpha induced genes: The present disclosure relates to identification of genes upregulated by interferon-α administration, in particular the human genes corresponding to the cDNA sequences in GenBank designated g4586459, g2342476, g3327161 and g4529886. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-α and...

20060099173 - Topical skin care composition: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma....

20060099175 - Full-length interferon gamma polypeptide variants: The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in...

20060099176 - Medicines including interferon and administering system thereof: The present invention discloses medicines including interferon and administering systems thereof, which have characteristics of the preparation according to the number of interferon on the surface of the cell and/or 2-5AS activity induced in the cell. The administering system of the present invention includes the first step of detecting the...

20060099177 - Methods for treating hiv infected subjects: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors...

20060099187 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060099186 - Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These...

20060099179 - Glutamic acid decarboxylase (gad) based delivery system: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding...

20060099184 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions vectors: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle...

20060099185 - Methods of treating anemia using recombinant adeno-associated virus virions: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed, The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the...

20060099178 - Novel use of adenoviruses and nucleic acids coding therefor: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably...

20060099180 - Retroviral delivery system: A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by...

20060099188 - Tumor-specific promoter: A DNA comprising a 609 bp base sequence from −559 to +50 when the first base sequence of exon 1 of the midkine gene, a human retinoic acid-responsive growth/differentiation factor was set as +1, or a DNA comprising a 251 bp base sequence from −213 to +38 when the transcription...

20060099183 - Use of recombinant adeno-associated virus vector (raav) for the prevention of smooth muscle cell proliferation in a vascular graft: A recombinant adeno-associated virus is used to transduce the cells of a tissue graft ex vivo. More specifically, rAAV encoding a therapeutic protein is delivered to a vascular graft to prevent smooth muscle cell proliferation or thrombosis in the graft. The cells are transfected ex vivo with the recombinant virus...

20060099182 - Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology....

20060099181 - Viral vectors having reduced virulence: The present invention provides recombinant vaccinia virus having a deletion of the region encoding the C-terminal seven amino acids of the E3L gene product and comprising exogenous DNA. Compositions comprising the recombinant vaccinia virus and methods of use thereof are also provided....

20060099194 - Composition and method for clusterin-mediated stem cell therapy for treatment of atherosclerosis and heart failure: Methods and compositions are disclosed for inhibiting, deterring or preventing apoptosis of cardiac myocytes, transplanted stem cells, vascular stem cells, and vascular smooth muscle cells by means of expressing or synthesizing clusterin. Also disclosed are methods and compositions for producing recombinant clusterin, or its biologically active peptides, and for induction...

20060099193 - Methods and materials for suppressing pain: Disclosed herein are methods and materials for suppressing pain that involve the production and implantation of stem cells genetically engineered to express pain suppression proteins. Specifically disclosed is a method of implanting mesenchymal stem cells engineered to express preproenkephalin....

20060099195 - Tumor cells with increased immunogenicity and uses therfor: Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using...

20060099196 - Photoprotective orally administrable composition for skin: An orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast, included into an orally acceptable carrier....

20060099197 - Probiotic, lactic acid-producing bacteria and uses thereof: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant...

20060099189 - Anti-cancer virus desensitization method: A mammalian subject having a tumor is treated by a method comprising administering to the subject an amount of a Newcastle disease virus effective to treat the subject, wherein the virus is administered to the subject in one or more cycles; at least one cycle comprises administering sequentially one or...

20060099191 - Cell-seeded tissue-engineered polymers for treatment of intracranial aneurysms: Methods and materials for treating intracranial aneurysms with a tissue-engineered biopolymer are disclosed. A novel technique has been developed which utilizes a tissue-engineering biopolymer (TEBP) with living endothelial cells such that the endothelial cells will produce a neoendothelium across the aneurysm ostium. Alternatively, biocompatible materials can be coated onto aneurysm...

20060099192 - Method for generating an expandable tissue culture from progenitor cells and tissue so generated: This invention relates to neuronal tissue which is suitable to restore neuronal deficits following transplantation. To reduce immunological side effects and to increase the microbiological and genetic safety of the tissue we propose tissue that does not contain glial cells and is maintained in vitro for prolonged periods. The method...

20060099190 - Method for transdifferentiating mesenchymal stem cells into neuronal cells: This inventive discloses a method for transdifferentiating mesenchymal stem cells into neuronal cells, which comprises increasing the level of a basic helix-loop-helix (bHLH) transcription factor in the mesenchymal stem cells, said cells being useful in cell therapy or gene therapy for treating brain neurological diseases such as Parkinson's disease, Alzheimer...

20060099198 - Platelets from stem cells: Human embryonic stem cells are induced to differentiate first into the hematopoietic lineage and then into megakaryocytes, the cells which generate platelets. The proper in vitro culture of megakaryocytes results in the production and shed of platelets. This makes possible, for the first time, the in vitro production of a...

20060099199 - Peroxiredoxin drugs for treatment of hiv-1 infection and methods of use thereof: The invention includes compositions comprising substantially purified peroxiredoxin that are useful in methods for the treatment and prevention of HIV-1 infection. The invention also includes methods for the treatment and prevention of HIV-1 infection comprising contacting a composition of the invention with a human patient. Additionally, the invention includes antibodies...

20060099200 - Pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger: The present invention relates to a treatment by pulmonary delivery of bioscavengers to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances....

20060099201 - Treating a mammal with a formulation comprising an antibody which binds ige: A method of treating a mammal with a formulation comprising an antibody which binds IgE as described....

20060099203 - B7-dc binding antibody: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to...

20060099205 - Bispecific single chain fv antibody molecules and methods of use thereof: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family....

20060099207 - High affinity antibodies against hmgb1 and methods of use thereof: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present...

20060099202 - Immunoglobulin construct containing tumor- specific p53bp2 sequenes for eliciting an anti-tumor response: The present invention provides immunoglobulins specific for p53BP2 ligand polypeptides. In a preferred embodiment, the present invention provides a variant of an immunoglobulin variable domain, wherein the immunoglobulin variable domain contains (A) at least one CDR region and (B) framework regions flanking the CDR, and the variant includes: (a) the...

20060099208 - Method of potentiating the therapeutic action of monoclonal and polyclonal antibodies: A method of potentiating the action of monoclonal/polyclonal antibodies against growth factors and their receptors by coupled conjugation with EFAs/PUFAs (optionally with a lymphographic agent) in the prevention and/or treatment of cancer, and inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, mixed connective tissue disorder, vasculitis....

20060099206 - Methods and compositions for improving recombinant protein production: Nucleic acid molecules modified to enhance recombinant protein, e.g., antibody, expression and/or reduce or eliminate mis-spliced and/or intron read-through (IRT) by-products are disclosed. The invention also provides methods for producing proteins devoid of mis-spliced and/or intron read-through by-products by the use of such vectors in host cells under cell culture...

20060099204 - Methods for antibody engineering: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of...

20060099209 - Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases: The invention concerns novel DNA and amino acid sequences of monoclonal antibodies. (mAbs) raised against lymphoblastoid cells and peptides to which the mAbs bind to. The invention also concerns diagnostic assays using said antibodies or peptides for detecting individuals with a high probability of having a malignant disease and, at...

20060099210 - Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders: The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia...

20060099211 - Safer, more potent human immunoglobulin preparations for treating alzheimer's disease: The invention provides anti-amyloid-β immunoglobulin preparations that have been treated to remove amyloid-β ligands....

20060099212 - Tnfalpha antagonists and methotrexate in the treatment of tnf-mediated disease: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation....

20060099214 - Cancer-linked gene as target for chemotherapy: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such...

20060099213 - Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells: This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The homoconjugates exert anti-growth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and does...

20060099217 - Eraap modulators regulate immune responses: An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an...

20060099216 - Peptide delivery: Disclosed is a chimaeric polypeptide comprising: a binding portion having specific binding affinity for a eukaryotic target cell surface component and an effector portion comprising an amino acid sequence capable of exerting a biological effect; whereby binding of the polypeptide to the cell surface component induces internalisation of at least...

20060099215 - Walnut and ryegrass allergens: A 30 kDa ragweed complete pollen extract disulfide protein allergen has been purified from ragweed pollen. IgE immunoblots with sera of ragweed, walnut and ryegrass sensitive patients indicated that the 30 kDa protein is a major allergen. The 30 kDa protein finds use in allergy testing and immunotherapy regimens....

20060099218 - Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity: The present invention relates to methods for enhancing exogenous epitope display on an MHC class I molecule through inhibition of TAP activity. Mammalian cell-infecting virus vectors encoding both a TAP inhibitory factor and an epitope-linked-β2m were constructed and introduced into mammalian cells. The present inventors succeeded in displaying on the...

20060099220 - Antibodies against and methods for producing vaccines for respiratory syncytial virus: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The...

20060099219 - Mutated hpv-16e7 polypeptide, pharmaceutical composition comprising it and its preparation process: The present invention is related to a mutated E7 polypeptide obtained from the human Papillomavirus HPV-16 as well as the pharmaceutical composition comprising it and its preparation process....

20060099221 - Method of screening anti-mycobacterial molecules: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the...

20060099222 - Novel mixture and compounds from mycelia of antrodia camphorata and use thereof: The present invention relates to novel mixtures and maleic and succinic acid derivatives from mycelium of Antrodia camphorata and the medical use thereof. The present invention relates to the composition or mycelium comprising the compounds of the invention....

20060099223 - Enzymetic hydrolysate of algae and method for preparing the same: An enzymatic hydrolysate of algae and a method for preparing the same are disclosed. After rehydrating dry algae, an insoluble pellet is digested by using a specific enzymatic reaction condition, so as to produce the soluble and bioactive enzymatic hydrolysate of algae. The enzymatic hydrolysate of algae, which comprises a...

20060099225 - Generation of virus-like particles and use as panfilovirus vaccine: In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburg with lipid rafts during assembly and budding, and the requirement of functional rafts for...

20060099224 - Methods and compositions concerning poxviruses and cancer: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In...

20060099226 - Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines: Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes...

20060099227 - Polysaccharide containing botulinum toxin pharmaceutical compositions and uses thereof: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000...

20060099228 - Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis: The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against Bacillus anthracis comprising a protective antigen (PA) and killed and optionally purified spores, obtained from mutating strains of Bacillus anthracis and their uses....

20060099229 - Vibrio cholerae strains vcusm1 and vcusm4, method of producing same, and vaccine derivatives thereof: Metabolic auxotroph of Vibrio cholerae 0139 synonym Bengal which has a mutation in its hem A gene and which is not capable of synthesizing aminolevulinic acid (ALA) de novo and which is obtained from a parent strain originally isolated from a patient's coproculture having all the identifying characteristics of Vibrio...

20060099230 - Novel formulations of eprosartan with enhanced bioavailability: The invention relates to the composition of a novel formulation of eprosartan with enhanced bioavailability. The formulation comprises of eprosartan or a salt, solvate, or hydrate thereof, a solubilizer, and an emulsifier. A process for manufacturing, and methods of using the formulation to block angiotensin II receptors and to treat...

20060099232 - Active oxygen eliminator and production method thereof: The object of the present invention is to provide an active oxygen eliminator having high active oxygen elimination effect and can be widely used in foods, drinks, and cosmetics as well as to provide the method for producing the active oxygen eliminator. To this end, the present invention provides an...

20060099231 - Make-up composition for keratin fibres such as eyelashes: The invention relates to a cosmetic make-up composition for keratin fibres. The inventive composition is characterised in that it comprises a non-aqueous solvent medium, at least 3 wt.-% of at least one wax in relation to the total weight of the composition, at most 20 wt.-% of water and/or water-soluble...

20060099233 - Granular formulation of neem seed extract and its process thereof: The present invention relates to an improved granular formulation of neem seed extract containing azadirachtin having enhanced storage stability, and the ability for gradual release of azadirachtin for application to plant rhizosphere. The formulation contains inert particulate as a carrier, at least one lipophilic substance as a deactivator/binder, optional colorant...

20060099237 - Antimicrobial medical articles containing a combination of anti-infective compounds, octoxyglycerin, salicylic acid, and sesquiterpenoids: Medical articles impregnated with antimicrobial compositions containing synergistic combinations of octoxyglycerin and other anti-infective compounds are disclosed. Such medical articles may include urinary catheters, central venous catheters, tracheal catheters, arterial grafts, wound dressings, sutures, or any other medical articles derived from polymeric substrates such as biomedical polyurethane, biomedical polyvinylchloride (PVC),...

20060099236 - Coated stents: The invention provides novel compositions and methods related to stents, such as coronary stents, comprising avicins, which are triterpene saponin compositions. In particular aspects of the invention, the avicins have growth-inhibiting properties and/or anti-inflammatory properties. In specific embodiments of the invention, the stent comprising the avicin reduces at least in...

20060099234 - Implant containing cultured cartilage cells and method for producing this implant: In order to regenerate joint defects in the human or animal body, the invention provides an implant that is placed in the joint area. Said implant is comprised of a supporting body and, in fact, is particularly comprised of a spongy bone of human or animal origin, has infiltrating channels...

20060099235 - Medical devices and compositions useful for treating or inhibiting restenosis: Medical devices and related methods for making and using same suitable for treating or inhibiting restenosis are proved. Specifically, compositions and methods for I kappa B alpha (IkBα)nuclear factor kβ (NFkβ) complex breakdown inhibition are provided. One embodiment includes a CRM-1 protein binding composition such as leptomycin B. Another embodiment...

20060099238 - Apparatus and methods for sealing a vascular puncture: Apparatus for sealing a puncture communicating with a blood vessel includes a porous carrier formed from lyophilized hydrogel or other material. The plug may include at least first and second hydrogel precursors and a pH adjusting agent carried by the porous carrier in an unreactive state prior to exposure to...

20060099239 - Dietary supplement for promoting removal of heavy metals from the body: A dietary supplement for removing or preventing the bio-accumulation of heavy metals in the body includes one or more chelators, precursors therefore, with at least one chelator capable of crossing the blood brain barrier to capture a heavy metal ion from a site in the central nervous system, and a...

20060099240 - Nutritional weight loss agent and method: The present invention relates to an agent that suppresses appetite and provides quick energy. According to at least one aspect of the present invention, a lollipop is provided that suppresses appetite and provides quick energy. The lollipop is made from a premixed herbal formula that is combined with a hard...

20060099241 - Adhesive preparation: The present invention aims at providing an adhesive preparation superior in adhesion operability. The adhesive preparation 10 of the present invention includes a substrate layer 1, an adhesive layer 3 and a separator 5 laminated in this order. The adhesive preparation 10 has an about quadrate planar shape. The separator...

20060099242 - Matrix for transdermal drug delivery: A transdermal drug delivery device involving a macromonomer-containing acrylate or methacrylate copolymer, a softener, and a drug. Also a pressure sensitive skin adhesive involving a macromonomer containing acrylate or methacrylate copolymer and a softener....

20060099244 - Liposomal formulation for oral administration of glutathione (reduced): The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related...

20060099243 - Liposome drug delivery: The invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration....

20060099248 - 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed....

20060099245 - Hydrodynamically balancing oral drug delivery system with biphasic release: The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance....

20060099247 - Liquid, gas and/or vapor phase delivery systems: This invention relates generally to liquid, gas and/or vapor phase delivery systems and, more particularly, to delivery systems that incorporate at least one layer, film and/or capsule that produces a liquid, gas and/or vapor phase compound or compounds for use therein....

20060099246 - Non-gelatin soft capsule system: A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for...

20060099253 - Antibiotic product formulation: This invention discloses an antibiotic formulation in an immediate release antibiotic dosage form, comprising an antibiotic, colloidal silicon dioxide, povidone, silicified microcrystalline cellulose, croscarmellose sodium, magnesium stearate and a coating, said formulation having a release profile wherein the Cmax is reached in less than five hours....

20060099252 - Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby: A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing...

20060099251 - Formulations of finasteride: This invention relates to pharmaceutical formulations of finasteride that include Gelucire®....

20060099249 - Modified release formulations of at least one form of tramadol: The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm...

20060099250 - Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets: The use of an aqueous solution of citric acid and a highly water-soluble sugar as a binder for the granulation of tablet excipients....

20060099255 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation...

20060099254 - Sustained release drug delivery system and method: The present invention relates to a pharmaceutical delivery system comprising a gel-like structure that comprises at least one water-soluble polymer, such as, for example, povidone or hydroxypropyl cellulose, and at least one fatty acid, such as, for example, stearic acid or lauric acid. The invention further relates to a sustained...

20060099256 - Microspheres and related processes and pharmaceutical compositions: The instant invention provides microspheres and related processes and pharmaceutical compositions useful in the controlled delivery of a wide variety of active ingredients. In one embodiment, the microspheres comprise an active ingredient dispersed within a polymeric composition comprising a first pH insensitive hydrophobic polymer and second pH sensitive hydrophobic polymer,...

20060099257 - Controlled drug delivery systems providing variable release rates: A controlled release dosage form with variable release rates comprising: 1) a bilayer or multilayer tablet core in which at least one of the layers contains one or more pharmaceutically active ingredients and at least one of the layers contains one or more rate controlling polymers; 2) a substantially insoluble...

20060099261 - Methods and formulations for making controlled release oral dosage form: Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating....

20060099262 - Methods and formulations for making controlled release oral dosage form: Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating....

20060099260 - Methods and formulations for making pharmaceutical compositions containing bupropion: Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating....

20060099258 - Propranolol formulations: Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and a sugar sphere; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone....

20060099259 - Propranolol formulations: Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone or about 60:40 to about 75:25 of ethylcellulose:hydroxypropylmethylcellulose....

20060099263 - Antidepressant dosage form: The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose....

20060099265 - Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer: [wherein R1 represents hydrogen or C1-5 alkyl; R2 represents C1-5 alkylene; R3 represents methylene or ethylene; R4 represents hydrogen or C1-4 acyl; R5 represents hydroxyl, optionally substituted aryl C2-8 alkoxyl, substituted C1-4 alkylamino, or amino having a residue of either an amino acid or a peptide derivative; n is an...

20060099264 - Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications: The invention concerns novel biodegradable polyaminoacid materials, useful in particular for vectoring active principle(s). The invention also concerns novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on said polyaminoacids. The invention aims at providing a novel polymer raw material, capable of being used for vectoring active principles and enabling optimal...

20060099267 - High-dosage extended-release formulation of gepirone: The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating...

20060099268 - Photochemically crosslinked collagen scaffolds and methods for their preparation: A method for producing collagen-based scaffolds with improved characteristics, which broadens the usage of collagen in tissue engineering and the products so produced are described. The method comprises reconstitution of three-dimensional collagen matrices from collagen monomer solution and crosslinking the matrix with a light source in the presence of a...

20060099266 - Slow release formulation of clarithromycin: The invention relates to an orally administrable pharmaceutical comprising an alginate matrix consisting of a water-soluble alginate salt and a complex salt of alginic acid, a macrolide, and an inorganic salt characterized in that the inorganic salt is capable of donating a proton and has a pKa value in water...

20060099270 - Production of small particles: The present invention relates to a method for producing particles of a compound of interest. In a method according to the invention a solution is provided of the compound of interest in a solvent. This solution is thickened or gelled and particles are formed. The invention further relates to a...

20060099269 - Pulmonary delivery of inhibitors of phosphodiesterase type 5: Provided herein are compositions of 1) diketopiperazine salts of PDE5 inhibitors, and 2) DKP microparticles having a PDE5 inhibitors thereon, as well as methods for the pulmonary delivery of these compositions for the treatment of pulmonary hypertension and sexual dysfunction(s)....

20060099271 - Residual solvent extraction method and microparticles produced thereby: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a...

20060099272 - Compositions and kits including dehydrated stinging capsules and methods of producing and using same: A dry composition-of-matter and a kit including dehydrated stinging capsules and methods of producing and using same are provided....

20060099273 - Sterile preparations and compositions including stinging capsules and methods of producing and using same: A sterile stinging capsule preparation and methods of producing and using same are provided....

20060099274 - Expulsive liquid for exterminating disease injury of plants: Expulsive liquid for exterminating disease injury of plants in a growing process, consisting of electrolyzed strong acid water produced by electrolysis of diluted aqueous solution of inorganic salt in an electrolytic cell with an ion-permeable membrane, the electrolyzed strong acid water being adjusted in pH to an extent of 2-4,...

20060099275 - Composition and method for increasing apoptosis in cancer cells: The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that...

20060099276 - Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate: The invention relates to a method for the preparation of a silicic acid comprising extrudate, comprising the steps of: i) forming of stabilised silicic acid, by hydrolysing a silicon compound into orthosilicic acid and/or oligomers thereof in the presence of a stabilizing agent, which is a quatemary ammonium compound, or...

20060099277 - Protein and fruit juice product: The invention is a product that produces a feeling of satiety, suppresses appetite and promotes a higher metabolic rate, while providing nutrients for a balanced meal in a fruit flavored meal substitute. The product for weight management comprises fruit juice and protein, and further comprises green tea extract comprising epigallocatechin...

20060099278 - Formulations containing melatonin, ginkgo biloba, and biotin: The present invention relates to a composition which comprises as active ingredients a combination of melatonin, ginkgo biloba and biotin. The composition is particularly suitable for producing formulations for topical application in the hair....

20060099279 - Novel anti-diabetic herbal formulation: The invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. rhizome extract used in treatment of diabetes and diabetic related diseases....

20060099280 - Water-soluble ginger root extract: Provided are a water-soluble ginger root extract which is a water extract or a hydrous alcohol extract of a ginger root and is substantially free of gingerols; and a hair growth inhibitor and a preparation for external use each containing the extract. The water-soluble ginger root extract of the present...

20060099281 - Herbal blood-pressure lowering and blood-lipid lower food: The invention provides a kind of food having blood-pressure lowering and blood-lipid lowering properties, the food include cold drink, beverage, flour and cake. The cold drink is obtained by boiling granular semen cassiae together with water in 1:5 proportion for 15 minutes, continuing heating under mild temperature for 30 minutes,...

20060099282 - Product of coromandel and method for its use: The present invention relates to a product of coromandel (Asystasia gangetica) and its use as a food by-product and medical value. By extracting the leaves of the coromandel (an antidiabetic agent or lactic acid bacteria promoter) for use in foods and animal feeds and dried goods, the manufacturing of a...

20060099283 - Leaf juice of plectranthus amboinicus for treating cancer and/or tumor: The present invention relates to a composition for treating tumor comprising an effective amount of leaf juice of Plectranthus amboinicus. The present invention also provides a method for producing the composition....

20060099284 - Composition containing an extract of fructus psoraleae for inhibiting anxiety and depression, improving memory and treating dementia: Disclosed is a composition comprising of an extract of Fructus Psoraleae for inhibiting anxiety and depression and improving memory. The composition can be used in medicaments and health care foods for preventing and treating anxiety and depression of modern people suffering from brain impairment caused by environmental factors, such as...

20060093551 - Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers: The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, R1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-18F-ethylamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2, N(11CH3)2, NH(CH2)nF, NH(CH2)n18F, N(CH3)(CH2)nF, N(CH3)—(CH2)n 18F, O—(CH2)nF, O—(CH2)n 18F, CONH(CH2)nF...

20060093552 - Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof: One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluoresence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates...

20060093553 - Cd26-based therapies for cancers and immune disease: Therapeutic methods comprising administering a composition comprising CD26 thereof in conjunction with chemotherapeutic agents or radiotherapeutic agents for the prevention and treatment of cancers are provided. Also provided are methods for potentiating immune responses comprising administering a composition comprising CD26....

20060093554 - Galenical formulations: This invention describes new galenical formulations that contain paramagnetic and diamagnetic perfluoroalkyl-containing compounds. The new formulations are suitable as contrast media for nuclear spin tomography....

20060093555 - Imaging inflammatory conditions using superparamagnetic iron oxide agents: The present invention is directed to the field of magnetic resonance imaging (MRI) using superparamagnetic iron oxide (SPIO) agents. In particular, the present invention is directed to cationic, nonagglomerated, nontoxic SPIO agents, methods for imaging conditions associated with inflammatory responses using the disclosed SPIO agents, and methods for managing inflammatory...

20060093556 - Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially...

20060093557 - Particulate composition: Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with...

20060093558 - Post-foaming dental mousse and methods utilizing the same: A post foaming oral care mousse is provided by the invention. The mousse includes at least a dentifrice composition and a compressed liquid propellant having a boiling point less than −10° C. The liquid propellant is blended into the mousse as an emulsion, and the emulsion is adapted to be...

20060093559 - Chewing gum composition with vegetal additives: A new chewing gum composition is disclosed. The chewing gum formulation contains extracts of plants and/or active principles contained in plant extracts. The plant extracts or plant-derived active principles can be encapsulated. A method for preparing the microcapsules is disclosed....

20060093560 - Immediate release film coating: The present invention is directed to a composition having a shell-forming component that contains a low-molecular weight water-soluble polymer and at least one gum capable of forming or contributing to the formation of thermoreversible gel, wherein the water-soluble polymer has a cloud point in an aqueous system within a temperature...

20060093561 - Method of treating microorganisms in the oral cavity: Method and kit for treating microorganisms in the oral cavity. Such microorganisms include those which contribute to periodontal disease and halitosis. The method comprises the steps of applying a photosensitizer to the interior of the mouth within and/or outside of the periodontal pockets, waiting a predetermined period of time; and...

20060093562 - Use of sodium decyl sulfate in toothpaste: Sodium decyl sulfate yields high foam production when added to aqueous compositions containing high levels of sodium bicarbonate. Sodium bicarbonate toothpastes and gels containing sodium decyl sulfate have high foaming properties and hold a desirable ribbon-type shape when applied to a toothbrush. Rheological properties and phase stability of such toothpastes...

20060093563 - Oral antimicrobial composition and use thereof in treating of dental plaque and gingivitis: An antimicrobial oral composition and use thereof in treating dental plaque and gingivitis, characterized in that said composition comprises: Active carbon as a surfactant: from 0.5% to 2% by weight. Carbopol 934 as a binding agent: from 2% to 3% by weight. Flavouring agents: from 0.05% to 6% by weight....

20060093564 - Color cosmetic compositions: A color cosmetic composition containing color impregnated spherules where the color is expressed from the spherule upon application of the cosmetic to the keratinous surface and the expressed spherule serves an uptake function on the keratinous surface; a cosmetic composition containing a rupturable spherule filled with color, and a method...

20060093565 - Pressed cosmetic powder and process for making: The present invention provides a cosmetic powder composition that has superior aesthetic properties over the prior art. The present invention is preferably a pressed powder cosmetic composition that includes silicone elastomer particles that have a JISA hardness index less than about 45. The cosmetic powder cosmetic compositions of the present...

20060093566 - Fucoidan-containing cosmetics: To find a substance which has a skin cosmeticizing effect such as prevention of skin aging, amelioriation of sensitive skin, or antipruritic action, and can serve as an effective ingredient for a hair-care product, thereby providing cosmetics comprising the effective ingredient. Concretely, there are provided cosmetics characterized in that the...

20060093567 - Method of inhibiting hair growth: Disclosed herein are a method of inhibiting hair growth, which comprises administering an inhibitor of elastase-like enzymes or a neutral endopeptidase inhibitor, and-use of an inhibitor of elastase-like enzymes or a neutral endopeptidase inhibitor for the preparation of a hair-growth inhibitor....

20060093568 - Composition comprising a block polymer and a film-forming agent: The present invention provides a cosmetic composition comprising, in a cosmetically acceptable organic liquid medium, at least one film-forming ethylenic linear block polymer, and another film former. The film former may be soluble or dispersible in the said organic liquid medium. The composition may include an aqueous phase, in which...

20060093569 - Method for preparing a cosmetic composition and cosmetic composition prepared by this method: A base composition comprising a fatty acid and an organic base to form at least partially a fatty acid organic soap is suitable for preparing a skin care composition by addition of relatively cold water....

20060093570 - Surface treatment: This invention describes a surface treatment composition, preferably for personal use, comprising at least one surfactant and at least two different organic acids and/or salts or organic acids, and wherein the total concentration of the organic acids and/or salts in the composition is at least 0.5% (w/v). The invention further...

20060093571 - Hair and skin protecting compositions based on esters or ethers of betulin: Personal care compositions and formulations, which include conventional concentrations of known hair and skin altering components and a cosmetically acceptable amount of oil-soluble betulin and allo-betulin esters or ethers derived from betulin or allo-betulin in effective amounts are disclosed....

20060093572 - Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone and 2,4,4'-trichloro-2' -hydroxydiphenyl ether: A polymerizable antimicrobial formulation for forming a wound closure adhesive comprising cyanoacrylate monomer, diiodomethyl-p-tolylsulfone and a halogenated hydroxyl diphenyl ether; and a method for closing the approximated edges of a wound with a polymeric film that substantially inhibits the growth of microorganisms, where the polymeric film is formed by use...

20060093573 - Drug composition with antimicrobial activity: The invention relates to the use of a polymeric guanidine derivative based on a diamine containing oxyalkylene chains between two amino groups, with the guanidine derivative representing a product of polycondensation between a guanidine acid addition salt and a diamine containing polyalkylene chains between two amino groups, for the production...

20060093574 - Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases: The current invention provides for methods of immunotherapy using a combination of epitope-specific and cytokine or anticytokine immunotherapy. The method provides for modulation of pathogenic immune responses and includes the identification of molecules comprising specific epitopes involved in a particular disease state of interest, administration of the epitope-specific molecule in...

20060093575 - Oxaliplatin anti-resistance agent: The invention concerns a method for detecting in vitro resistance of cancer cells to an oxaliplatin treatment characterized in that it consists in measuring mitochondrial apoptosis of cancer cells being treated or capable of being treated or to be treated with oxaliplatin....

20060093576 - Stabilized liquid polypeptide-containing pharmaceutical compositions: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of...

20060093577 - Combination anti-viral compositions and methods of use: The present disclosure relates generally to the use of castanospermine in combination with another therapeutic agent to treat or prevent infections caused by or associated with a virus of the Flaviviridae family, particularly infections caused by or associated with Hepatitis C virus (HCV), and to the use of such compounds...

20060093579 - Human recombinant beta-interferon with improved solubility: The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine,...

20060093578 - Method and composition for treating multiple sclerosis: A method of treating multiple sclerosis including administering Interferon-β and a phosphodiesterase inhibitor in combination in a therapeutically effective amount....

20060093581 - Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both: methods for obtaining same; and their uses: A method for obtaining lineage committed human cells imbued with enhanced proliferative potential, biological function, or both, comprising culturing lineage committed human cells under physiologically acceptable liquid culture conditions, where the liquid culture medium is replaced at a rate and for a time sufficient to obtain the human lineage committed...

20060093580 - Tolerogenic vaccine and method: Methods and compositions are provided for treating autoimmune diseases such as diabetes, rheumatoid arthritis, inflammatory bowel disease, and other conditions involving undesired immune responses such as allergies, including food allergies, and graft-versus-host disease. In one embodiment disclosed, regulatory/suppressor T cells are selected or expanded in culture using a phospholipase D...

20060093585 - Compounds and methods to enhance raav transduction: Agents and methods to alter rAAV transduction are provided....

20060093584 - Intravascular delivery of nucleic acid: Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic...

20060093582 - Listeria-based and llo-based vaccines: This invention provides methods of treating and vaccinating against an antigen-expressing tumor and inducing an immune response against a sub-dominant epitope of antigen, comprising a fusion of an LLO fragment to the antigen or a recombinant Listeria strain expressing the antigen. The present invention also provides recombinant peptides comprising a...

20060093583 - Targeted infusion of agents against parkinson's disease: A system and method for treating Parkinson's disease by delivery of an agent within the brain. At least one image of a target region is acquired, and at least one magnetic resonance diffusion tensor imaging (MR-DTI) scan of the target region is acquired. A diffusion tensor is calculated from the...

20060093590 - Pseudotyped retroviruses: Pseudotyped retroviruses having viral glycoproteins with modified O glycosylation regions are provided. Also provided are methods for making the pseudotyped retroviruses of the present invention and for using the pseudotyped retroviruses for transduction of target cells. Cells for stably producing the pseudotyped retroviruses or the present invention are also provided....

20060093589 - Vp2-modified raav vector compositions and uses therefor: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides,...

20060093591 - Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions: The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans, in combination with a bifidogenic oligosaccharides or other cholesterol-reducing agents for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions....

20060093593 - Pro-biotic broad-spectrum nourishment preparation in powder, liquid, paste, or gas form: A pro-biotic broad-spectrum nourishment preparation for employment as a food additive. The preparation provides an improvement of extraction in the nourishment of animals and the increase of immunity against diseases when consumed by animals in their food. Favored formulas employ a number of food additives including one or a combination...

20060093592 - Synbiotics: A novel product comprising a mixture of probiotic and prebiotic ingredients for the treatment of IBS, IBD, Crohn's disease, antibiotic induced diarrhea and other bowel disorders is described herein. Stabilized rice bran derivatives, including stabilized rice bran, RiSolubles, RiceMucil, and Cea100, are used as the source of prebiotics. The prebiotic...

20060093594 - Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions: A method of preparing an ultra-cleansed lactoferrin preparation, termed treatment for contaminant reduction (TCR) is provided which includes the steps of treating commercial lactoferrin preparation with at least one each of surfactants, antioxidants and polyphenols to form purified lactoferrin (LF-TCR) and drying the LF-TCR. Additionally a therapeutic lactoferrin composition is...

20060093588 - Device for bio-affinity material: Bio-affinity material containing at least one biologically active saccharide which is covalently bound via at least one spacer to a cross-linked matrix and that the material is autoclaved. Apparatus for contacting body fluids with the bio-affinity material is disclosed....

20060093586 - Generation and differentiation of adult stem cell lines: The present invention teaches a new method of stem cell generation involving the establishment of a mesenchymal cell culture, induction of epithelial marker expression and isolation and cloning of the cells expressing epithelial markers and expansion of these cell lines. Further processes are described for a two-step method to induce...

20060093587 - Transplants for myocardial scars: A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart....

20060093596 - Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish: There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening...

20060093597 - Methods of treating involuntary facial spasms and facial wrinkles: The invention describes antibiotics, muscle relaxants and plant extracts that have neuromuscular blockade effects as well as methods of use thereof. These compounds can be used in the same clinical settings as botulinum toxin and may be used topically, thereby providing an advantage over botulinum toxin in terms of application...

20060093595 - Methods, compositions and kits for treating damage to excitable tissue: Drug cocktails including protease inhibitors, sodium channel blockers and corticosteroids are described. The use of these drug cocktails in treatment of damage due to injury to excitable tissue is discussed. The use of the drug cocktails in the treatment or prevention of degenerative conditions of the central nervous system and...

20060093598 - Stabilized liquid polypeptide-containing pharmaceutical compositions: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of...

20060093599 - Anti-properdin antibodies, and methods for making and using same: The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly...

20060093600 - Antibodies to cd40: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies...

20060093601 - Humanized anti-beta7 antagonists and uses therefor: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies....

20060093602 - Inflammatory mediator antagonists: The present invention relates to the use of an antagonist of OSM such as an antibody or small molecule in the manufacture of a medicament for the treatment or prophylaxis of an inflammatory arthropathy or inflammatory disorder, and the use of OSM in screening for such antagonists....

20060093603 - Erbb4 antagonists: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing...

20060093606 - Compositions and methods of using angiopoietin-like 4 protein: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration....

20060093607 - Inhibitors of angiopoietin-like 4 protein, combinations, and their use: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse...

20060093604 - Method of treatment and prophylaxis: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of inflammatory conditions such as but not limited to chronic immune-mediated inflammatory diseases. The present invention further provides pharmaceutical compositions comprising agents which inhibit one or more inflammatory cytokines and/or which down-regulate expression...

20060093605 - Method of treatment and prophylaxis: The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells....

20060093608 - Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target: Low molecular weight protein tyrosine phosphatase (LMW-PTP) is identified as a novel diagnostic and therapeutic target in cancer diagnosis, prognosis and treatment. The invention provides diagnostic and treatment methods useful in connection with cancers expressing LMW-PTP and, optionally, EphA2 receptor. Also provided is a screening method that utilizes changes in...

20060093609 - Vaccine against yersinia comprising one or two antibodies, one specific for yersinia pestis f1-antigen and the other one for yersinia pestis v-antigen: The use of (i) an antibody specific for Yersinia pestis F1-antigen, or a binding fragment thereof, or (ii) an antibody specific for Yersinia pestis V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by Yersinia...

20060093610 - Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats 06 of pseudomonas aeruginosa: The present application relates to a human monoclonal antibody specific for the serotype IATS O6 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to...

20060093611 - Method: There is described a method of magnetically manipulating a cell in vivo which comprises the association of a magnetisable particle with a cell. More particularly, there is described a method of magnetically manipulating a cell which comprises the association of a magnetisable particle with a cell characterised in that the...

20060093614 - Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof: The present invention provides compositions and methods for treating or preventing vascular-associated disorders....

20060093613 - Soluble t cell receptor: The present invention relates to a recombinant soluble T cell receptor. The T cell receptor (TCR) is refolded and comprises a recombinant TCR α or γ chain extracellular domain having a first heterologous C-terminal dimerization peptide; and a recombinant TCR β or δ chain extracellular domain having a second C-terminal...

20060093615 - Tumor antigen based on products of the tumor suppressor gent wt1: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising...

20060093612 - Use of heat shock proteins to enhance efficacy of antibody therapeutics: The present invention relates to methods and pharmaceutical compositions useful for the prevention and treatment of any disease wherein the treatment of such disease would be improved by an enhanced immune response, such as infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), or neurodegenerative or amyloid diseases. In particular,...

20060093616 - Process for vaccinating eucaryotic hosts and for protecting against sars-cov infection: The present invention relates to a process for vaccinating humans and for protecting against SARS-CoV infection....

20060093617 - Peptides for inducing a ctl and/or htl response to hepatitis c virus: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and...

20060093618 - Agaricus blazei murill extract capable for preventing cancer induction or metastasis: A foodstuff capable of preventing the induction or metastasis of cancer is provided. In particular, an Agaricus blazei Murill extract comprising an ingredient capable of preventing the induction or metastasis of cancer is provided. The ingredient can be a chromatographic main elute fraction of 100 to 2000 molecular weight, obtained...

20060093619 - Medicament for prevention and treatment of bone fracture and osteoporosis: The present invention provides a pharmaceutical composition which can be used to prevent and treat bone fracture and osteoporosis. The composition is composed of Semen lactucae sativae 0.1-1, Lignum aquilariae resinatum 2-20, Fructus oryzae 1-5, Resina boswelliae carterii 0.1-1, Rhizoma atractylodis macrocephalae 0.1-1 and Semen cuscutae 0.1-1. The whole or...

20060093620 - Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods: The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be...

20060093621 - Development of a live, attenuated, recombinant vaccine for brucellosis: A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e....

20060093622 - Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same: The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E. rhusiopathiae and H. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of...

20060093623 - Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection: Inactivated whole HIV of a particular subtype is used for vaccines and pharmaceutical compositions containing the vaccines. The vaccines can be used to treat individuals chronically infected with HIV, by inducing a protective cellular immune response in the individuals against the same HIV subtype used to produce the vaccine....

20060093624 - Botulinum toxin for treating muscle contracture: The invention provides for the use of a botulinum toxin to treat contracture, such as muscle contracture, in patients by transdermal administration of the botulinum toxin....

20060093625 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting...

20060093626 - Vaccine: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular the present invention relates to specific advantageous pneumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid of aluminium-based adjuvant....

20060093627 - Method of protecting chronic infections: The present invention is directed to a method of protecting an animal against a chronic disease, the disease being caused by an infectious organism which undergoes more than one stage in its life cycle or undergoes more than one infectious cycle. The method comprises: a) administering to the animal a...

20060093628 - Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immonomodulator, its production process and formulation: An immunomodulator consisting of a protein aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride, containing 11.6±4.0% of total lipids, (22.7±5.0% of palmitoleic acid, 42.9±2.0% of linoleic acid, and 32.0±3.0% of oxidated linoleic acid), 20.1±0.9% of magnesium ions, 10.0±3.3% of ammonium ions, 45.2±2.7% of phosphate, and 0.49±0.01% of protein (Asp 7.19%, Thr...

20060093632 - Compositions for controlled delivery of pharmaceutically active compounds: The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal by injection. When the pharmaceutical compositions are administered to an animal by injection, they form a...

20060093629 - Dye-free pharmaceutical suspensions and related methods: A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an...

20060093630 - Dye-free pharmaceutical suspensions and related methods: A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; and an effective amount of an opacifier,...

20060093631 - Dye-free pharmaceutical suspensions and related methods: A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the dye-free pharmaceutical suspension has a...

20060093636 - Allantoin-containing skin cream: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about...

20060093633 - Cosmetic and/or dermatological preparation comprising 2,3-dibenzylbutyrolactones: Cosmetic and/or dermatological preparation containing one or more 2,3-dibenzylbutyrolactone derivatives and/or their glycosides besides optionally additional cosmetic and/or dermatological active ingredients, auxiliary agents, and additives....

20060093635 - Oil-in-water emulsion type cosmetic preparation: The present invention provides an oil-in-water emulsion type cosmetic preparation containing (A) at least one selected from the group consisting of ester compounds which are reaction products of ditrimethylolpropane with fatty acid, polycondensates of ditrimethylolpropane with polycarboxylic acid, polycondensates of the ester compound with polycarboxylic acid, polycondensates of fatty acid...

20060093634 - Personal care compositions and concentrates for making the same: The present invention relates to color stable personal care compositions that provide anti-oxidiation, moisturization, and/or prevent biodegradation in personal care formulations. These compositions contain erythorbic acid or a salt thereof, caffeic acid or a salt thereof, δ-gluconolactone, or a mixture thereof. The present invention further relates to methods of moisturizing...

20060093637 - Phosphonates and derivatives thereof as enhancers of the activity of insecticides: An insecticidal composition having as an adjuvant a phosphonate or an alkoxylated derivative or dimer thereof. Preferred phosphonates are bis-(2-ethylhexyl)-2ethylhexylphosphonate, bis-(2-ethylhexyl)-octylphosphonate and bis-(butyl)butylphosphonate....

20060093638 - Sustained pheromone releaser: Provided is a sustained releaser of a sex pheromone having a high release rate, especially preferably of a sex pheromone of an aliphatic acetate compound having 10 to 16 carbon atoms, wherein the release of the sex pheromone is controlled so that it can be released at a constant rate...

20060093639 - Method and device for destroying body tissue: In general, the invention is directed to devices and methods for destroying targeted body tissue. A hydrogel implant, configured to be implanted in a target tissue, includes an associated chemical agent, such as a proteolytic chemical agent. When implanted in the targeted tissue, the implant expands and discharges the chemical...

20060093645 - Glass scaffolds with controlled resorption rates and methods for making same: The present invention relates to resorbable glass scaffolds for use in biological applications and methods for making same. Specifically, these scaffolds are composed of phosphate glass fibers, where the rate of dissolution into biological fluids is controlled by the length of time the glass is held above its melt temperature...

20060093643 - Medical device for delivering therapeutic agents over different time periods: A medical device comprising a surface coated by at least two coating regions comprising a therapeutic agent is disclosed. These coating regions allow for the release of the therapeutic agent over different time periods....

20060093642 - Method of incorporating carbon nanotubes in a medical appliance, a carbon nanotube medical appliance, and a medical appliance coated using carbon nanotube technology: A method of coating an article is provided. The method includes: preparing a solution including a bioactive agent and a carbon nanotube precursor; treating the solution to form carbon nanotubes; and applying the solution to the article. A method of producing a medical device is provided. The method includes: forming...

20060093641 - Methods and apparatus for treating an injured nerve pathway: Methods and apparatus are provided for treating an injured or severed nerve pathway, wherein one or more microporous tubes are implanted into the nerve pathway to bridge the injured or severed region. A bioactive matrix including stem cells and nutrients is disposed within the microporous tube to facilitate growth of...

20060093644 - Methods of administering microparticles combined with autologous body components: Microspheres to be implanted into a patient are metered and mixed with fluids, cells, or tissues withdrawn from the patient's own body, and reinserted into the patient's body to achieve augmentation, repair or other treatment of the patient's tissue....

20060093640 - Osteoinductive biomaterials: In a method of isolating osteogenic protein from bone, in which an osteogenic protein-containing fraction is extracted from bone and enriched by a sequence of enrichment steps selected from ultrafiltration and chromatography, the invention provides the improvement of removing higher molecular weight components from the osteogenic protein-containing fraction prior to...

20060093646 - Orthopedic and dental implant devices providing controlled drug delivery: Implantable prosthetic devices are provided for controlled drug delivery, for orthopedic and dental applications. The device may include a prosthetic device body having at least one outer surface area; two or more discrete reservoirs located in spaced apart positions across at least a portion of the outer surface area, the...

20060093648 - Hydrogels for orthopedic repair: Hydrogels intended for orthopedic applications, including repair and regeneration of cartilage, bone, joint surfaces and related tissues, must possess greater strength and toughness than hydrogels used in soft tissue repair. A hydrogel formulation is provided which has high strength, toughness, a suitable mechanical modulus and low equilibrium hydration. It may...

20060093647 - Multiple layer coating composition: A multiple layer coating for application upon surfaces of an implantable medical device, a first layer of such coating includes an anti-thrombogenic factor and a second layer of such coating includes a hyperplasia inhibiting factor that is releasably contained therein. The hyperplasia inhibiting factor is controllably released from the multiple...

20060093649 - Food composition for recovery from fatigue: In the present application are disclosed a food composition for recovery from fatigue, comprising, as an effective ingredient, an extract of migratory fish such as a Perciformes Scombrina, or a composition of the make-up similar to the extract, according to which food composition can be provided a food composition for...

20060093651 - Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials: This invention relates to drinks and foods having osteogenetic function, each of which comprises as an active ingredient an effective amount of a culture of a propionic acid bacterium and/or a lactic acid bacterium, said culture containing 2-amino-3-carboxy-1,4-naphthoquinone; and preventives and/or remedies for metabolic bone diseases, each of which comprises...

20060093650 - Methods for regulating weight and size of animals: The invention provides methods and compositions for regulating weight and size in animals....

20060093652 - Collagen product with an alginate sheath and method for producing the same: A collagen product with an alginate sheath and a method for producing the same are described. A first solution containing at least an alginate is prepared. A second solution containing collagen and at least an alkaline earth metallic salt is then prepared. The second solution is spun through a spinneret...

20060093653 - Periadventitial delivery device: The subject invention pertains to a biodegradable matrix material which is provided in a form that can be wrapped around a body part, in combination or impregnated with an agent that can be delivered to treat a condition via the adventitial surface of a body part, the agent being in...

20060093655 - Method for making a reinforced absorbable multilayered hemostatic wound dressing: The present invention is directed to a method of making a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and fibrinogen....

20060093654 - Thin aqueous cataplasm material: A thin aqueous cataplasm prepared by laminating an adhesive layer (base) having specified constituents on a support which consists of a fiber film prepared by heat-fusing a soft plastic resin on a composite fiber prepared by entangling a natural fiber and a soft plastic fiber, or consists of a fiber...

20060093658 - Apparatus and method for transdermal delivery of desmopressin: An apparatus and method for transdermally delivering desmopressin comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the...

20060093657 - Patch containing a substance selected from tars having reducing characteristics in dermatology: A patch consisting of a porous or occlusive woven, non-woven or plastic support, to one face of which is applied a skin adhesive polymer layer containing tars used as reducers or resolvents in dermatology, in particular ichthyol. The patch is able to gradually release the active substances in order to...

20060093656 - Warming patch: A warming patch 10 comprising a support 2 and adhesive layer 1 disposed on at least one surface of this support 2, wherein the adhesive, layer 1 contains a warming material, 1-menthol and polyethylene glycol as an irritation reducing agent....

20060093659 - Hydroxide-releasing agents as skin permeation enhancers: A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface...

20060093660 - Compositions for treatment with glucagon-like peptide, and methods of making and using the same: In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1....

20060093662 - Liposomal camptothecins and uses thereof: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis....

20060093661 - Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system....

20060093663 - Drug delivery system and drug capsule and transmitter used therefore: Release control of a drug in a drug capsule existing in a subject is extremely simply and accurately performed. A non-contact type IC chip which generates a voltage on the basis of a release command signal from the outside, and a piezoelectric actuator which is driven by the voltage, are...

20060093664 - Natural vitamin e compositions with superior antioxidant potency: Compositions for increased antioxidant potency of natural vitamin E (d-alpha-tocopherol), comprising alpha-, beta-, delta-, and gamma-forms of tocopherols and tocotrienols are disclosed. All of these compositions provide 400 International Units (IU), based on one mg of d-alpha-tocopherol provides 1.49 IU. These compositions showed antioxidant activities superior to natural d-alpha-tocopherol. These...

20060093669 - Calcium hypochlorite blended tablets: A non-Division 5.1 Oxidizer tablet consisting essentially of a blend of hydrated calcium hypochlorite with magnesium sulfate heptahydrate, wherein the blend contains at least about 17% by weight of water based on the total weight of the blend; contains from about 0.1% to about 10% of lime based on the...

20060093666 - Formulations for tyrosine kinase inhibitors: The present invention is related to a powder, powder blend or granulation formulation of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, a tyrosine kinase inhibitor, which is adapted for reconstitution with a diluent. This invention is also related to a prepared aqueous suspension, or dispersion, formulation, particularly to a stable oral pharmaceutical formulation, comprising granules of...

20060093668 - Melt granulated composition and modified release dosage form prepared from said composition: Solid modified release dosage forms, prepared from melt granulated compositions comprising (A) one or more hydrophilic cellulose ether polymers, (B) a hydrophilic melt binder, and (C) a therapeutically active ingredient....

20060093667 - Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency: A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manufacture of low dosage tablet compositions....

20060093665 - Method to improve surface properties of pharmaceutical tablets: The invention provides a method to improve surface properties of tablets having a matrix consisting of at least 55% of a cellulose ether, characterised in that the method comprises briefly exposing the tablets to a hydrous solvent....

20060093671 - Controlled release galantamine composition: The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions....

20060093670 - Sustained-release composition process for producing the same and preparation thereof: The present invention provides a sustained-release composition by which a sustained-release effect can be obtained for a long time when injecting microparticles of the composition in an amount that can be subcutaneously or intramuscularly injected to a human with ease and without pain. The composition comprises porous hydroxyapatite microparticles having...

20060093672 - Biodegradable oxidized cellulose esters: The present invention relates to the preparation of a series of oxidized cellulose esters suitable for use as a drug carrier in the development of biodegradable controlled and/or sustained release pharmaceutical, agricultural, and veterinary compositions, such as films, compacts, microspheres, and pellets. The esters are prepared by acylation of oxidized...

20060093674 - Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof: A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents,...

20060093673 - Controlled release of anti-arrhythmic agents: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated along with...

20060093675 - Intravaginal treatment of vaginal infections with metronidazole compositions: The present invention provides a buffered non-flowing composition suitable for the treatment of bacterial vaginosis. The composition includes metronidazole in a concentration of about 0.50% (w/w) to about 1.50% (w/w). The metronidazole is present together with a buffer system in a physiologically tolerable medium. The buffer system provides an acidic...

20060093676 - Ascorbic acid stability: Stable ascorbic acid-dextran conjugates, useful as active constituents in food, pharmaceutical as well as cosmeceutical applications, are described....

20060093677 - Methods for making pharmaceutical formulations comprising deagglomerated microparticles: Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent; (ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles; (iii) blending the...

20060093678 - Methods for making pharmaceutical formulations comprising deagglomerated microparticles: Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent; (ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles; (iii) blending the...

20060093680 - Coated particles and pharmaceutical dosage forms: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating....

20060093679 - Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve: The present invention is concerned with solid, single-dose dosage forms for an increased rate of release of slightly soluble active ingredients. The dosage forms are based on a coherent matrix which disintegrates rapidly in physiological fluids. The matrix comprises one or more slightly soluble active ingredients in the form of...

20060093681 - Method and apparatus for the administration of co: The present invention relates to a method and apparatus for the administration of carbon monoxide (CO) to a patient. It allows the safe and effective use of carbon monoxide as a medicament....

20060093682 - Stable cleanser compositions containing sulfur: The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders....

20060093683 - Stable cleanser compositions containing sulfur: The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders....

20060093684 - Seleniferous composition for producing antioxidase in vivo: Seleniferous composition is provided which comprises Se-methylseleno-cysteine (MeSeCys: SeCH3—CH2—CHNH2—COOH) or derivative thereof. When human or animal body ingests the seleniferous composition, their living body naturally produces enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione-S-transferase (GST) for decomposing active oxygen to positively prevent and treat cancer....

20060093685 - High mineral content dietary supplement: Liquid dietary supplements include vitamins, macro minerals, trace minerals, high Oxygen Radical Absorption Capacity (ORAC) compounds, and optionally fulvates. Despite the tendency of minerals in such a liquid mineral and vitamin supplement to precipitate and for the ingredients to quickly degrade, particularly at high ORAC values and low pH, embodiments...

20060093686 - Lectin for checking blood type, blood type checking reagent containing the lectin, and method of checking blood type using the blood type checking reagent: Lectin for checking a blood type is extracted from seeds of bitter gourd, balsam pear, or Momordica charantia. A blood type checking reagent includes the lectin. The lectin extracted from seeds of bitter gourd preferably has a molecular weight between 100,000 and 170,000 measured with poly-acrylamide gel electrophoresis in existence...

20060093687 - Combinations of a vanilloid antagonist and an nsaid for the treatment of pain: A method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, a vanilloid VR-1 antagonist or a pharmaceutically acceptable derivative thereof and an NSAID or a pharmaceutically acceptable derivative thereof, wherein said VR-1 antagonist or said NSAID may optionally...

20060093688 - Nutritional olive oil based compositions, and method of consumption thereof: A nutritional, olive-oil based, at least semi-solid product for oral intake and for topical application, the product including: (a) an olive oil; (b) an omega-3 fatty acid source, and (c) an emulsifier, the components being intimately mixed so as to form the at least semi-solid product, and wherein a Total...

20060093689 - Skin cosmetics: Skin cosmetics which are excellent in moistness and persistency of moisture-keeping effect, show light sense of touch when used and have excellent periodical stability. In addition, there are provided skin cosmetics which do not cause stickiness after their use, are excellent in rough skin improving and preventing effects, wrinkle preventing...

20060093690 - Novel therapeutic use of polypodium extracts: New therapeutic use of Polypodium extract. A new use of Polypodacea genus extracts is described for the treatment of fibrotic pathologies, such as, scleroderma, pulmonary fibrosis, atherosclerosis, bone marrow fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, Dupuytrem's disease and, specially, Peyronie's disease; said fibrotic pathologies are produced by...

20060093691 - Composition for oral or corporeal hygiene or for health comprising seeds or ground material or protein extracts based on seeds of a plant of the genus moringa: The invention concerns a deodorant composition of a composition for oral or corporeal hygiene, or for health, characterized in that it comprises seeds of a plant of the genus Moringa as such or ground or in the form of a protein extract....